Analysis	O
of	O
the	O
ligand-binding	B-protein
domain	I-protein
of	O
human	B-protein
retinoic	I-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
by	O
site-directed	O
mutagenesis	O
.	O

Three	O
subtypes	O
of	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RAR	B-protein
)	O
,	O
termed	O
RAR	B-protein
alpha	I-protein
,	O
RAR	B-protein
beta	I-protein
,	O
and	O
RAR	B-protein
gamma	I-protein
,	O
have	O
been	O
described	O
.	O

They	O
are	O
composed	O
of	O
different	O
structural	B-protein
domains	I-protein
,	O
including	O
distinct	O
domains	O
for	O
DNA	O
and	O
ligand	O
binding	O
.	O

RARs	B-protein
specifically	O
bind	O
all-trans-retinoic	O
acid	O
(	O
RA	O
)	O
,	O
9-cis-RA	O
,	O
and	O
retinoid	O
analogs	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
functional	O
role	O
of	O
cysteine	O
and	O
arginine	O
residues	O
in	O
the	O
ligand-binding	B-protein
domain	I-protein
of	O
hRAR	B-protein
alpha	I-protein
(	O
hRAR	B-protein
alpha-LBD	I-protein
,	O
amino	B-protein
acids	I-protein
154	I-protein
to	I-protein
462	I-protein
)	O
.	O

All	O
conserved	O
cysteine	O
and	O
arginine	O
residues	O
in	O
this	O
domain	O
were	O
mutated	O
by	O
site-directed	O
mutagenesis	O
,	O
and	O
the	O
mutant	B-protein
proteins	I-protein
were	O
characterized	O
by	O
blocking	O
reactions	O
,	O
ligand-binding	O
experiments	O
,	O
transactivation	O
assays	O
,	O
and	O
protease	B-protein
mapping	O
.	O

Changes	O
of	O
any	O
cysteine	O
residue	O
of	O
the	O
hRAR	B-protein
alpha-LBD	I-protein
had	O
no	O
significant	O
influence	O
on	O
the	O
binding	O
of	O
all-trans	O
RA	O
or	O
9-cis	O
RA	O
.	O

Interestingly	O
,	O
residue	O
C-235	O
is	O
specifically	O
important	O
in	O
antagonist	O
binding	O
.	O

With	O
respect	O
to	O
arginine	O
residues	O
,	O
only	O
the	O
two	O
single	O
mutations	O
of	O
R-276	O
and	O
R-394	O
to	O
alanine	O
showed	O
a	O
dramatic	O
decrease	O
of	O
agonist	O
and	O
antagonist	O
binding	O
whereas	O
the	O
R272A	O
mutation	O
showed	O
only	O
a	O
slight	O
effect	O
.	O

For	O
all	O
other	O
arginine	O
mutations	O
,	O
no	O
differences	O
in	O
affinity	O
were	O
detectable	O
.	O

The	O
two	O
mutations	O
R217A	O
and	O
R294A	O
caused	O
an	O
increased	O
binding	O
efficiency	O
for	O
antagonists	O
but	O
no	O
change	O
in	O
agonist	O
binding	O
.	O

From	O
these	O
results	O
,	O
we	O
can	O
conclude	O
that	O
electrostatic	O
interactions	O
of	O
retinoids	O
with	O
the	O
RAR	B-protein
alpha-LBD	I-protein
play	O
a	O
significant	O
role	O
in	O
ligand	O
binding	O
.	O

In	O
addition	O
,	O
antagonists	O
show	O
distinctly	O
different	O
requirements	O
for	O
efficient	O
binding	O
,	O
which	O
may	O
contribute	O
to	O
their	O
interference	O
in	O
the	O
ligand-inducible	O
transactivation	O
function	O
of	O
RAR	B-protein
alpha	I-protein
.	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BroLOGY	NULL
,	NULL
Oct.	NULL
1996	NULL
,	NULL
p.	NULL
5386-5392	NULL
0270-7306/96/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1996	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

16	NULL
,	NULL
No	NULL
.	NULL

10	NULL
Analysis	NULL
of	NULL
the	NULL
Ligand-Binding	NULL
Domain	NULL
of	NULL
Human	NULL
Retinoic	NULL
Acid	NULL
Receptor	NULL
«	NULL
by	NULL
Site-Directed	NULL
Mutagenesis	NULL
FRANCOIS	NULL
P.	NULL
Y.	NULL
LAMOUR	NULL
,	NULL
PILAR	NULL
LARDELLI	NULL
,	NULL
anp	NULL
CHRISTIAN	NULL
M.	NULL
APFEL*	NULL
Preclinical	NULL
Research	NULL
,	NULL
F.	NULL
Hoffmann-La	NULL
Roche	NULL
Ltd.	NULL
,	NULL
CH-4070	NULL
Basel	NULL
,	NULL
Switzerland	NULL
Received	NULL
15	NULL
May	NULL
1996/Returned	NULL
for	NULL
modification	NULL
24	NULL
June	NULL
1996/Accepted	NULL
9	NULL
July	NULL
1996	NULL
Three	NULL
subtypes	NULL
of	NULL
retinoic	NULL
acid	NULL
receptors	NULL
(	NULL
RAR	NULL
)	NULL
,	NULL
termed	NULL
RARa	NULL
«	NULL
,	NULL
RAR	NULL
,	NULL
and	NULL
RARy	NULL
,	NULL
have	NULL
been	NULL
described	NULL
.	NULL

They	NULL
are	NULL
composed	NULL
of	NULL
different	NULL
structural	NULL
domains	NULL
,	NULL
including	NULL
distinct	NULL
domains	NULL
for	NULL
DNA	NULL
and	NULL
ligand	NULL
binding	NULL
.	NULL

RARs	NULL
specifically	NULL
bind	NULL
all-frans-retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
,	NULL
9-cis-RA	NULL
,	NULL
and	NULL
retinoid	NULL
analogs	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
functional	NULL
role	NULL
of	NULL
cysteine	NULL
and	NULL
arginine	NULL
residues	NULL
in	NULL
the	NULL
ligand-binding	NULL
domain	NULL
of	NULL
hRAR	NULL
«	NULL
(	NULL
hRAR	NULL
«	NULL
-LBD	NULL
,	NULL
amino	NULL
acids	NULL
154	NULL
to	NULL
462	NULL
)	NULL
.	NULL

All	NULL
conserved	NULL
cysteine	NULL
and	NULL
arginine	NULL
residues	NULL
in	NULL
this	NULL
domain	NULL
were	NULL
mutated	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
,	NULL
and	NULL
the	NULL
mutant	NULL
proteins	NULL
were	NULL
characterized	NULL
by	NULL
blocking	NULL
reactions	NULL
,	NULL
ligand-binding	NULL
experiments	NULL
,	NULL
transactivation	NULL
assays	NULL
,	NULL
and	NULL
protease	NULL
mapping	NULL
.	NULL

Changes	NULL
of	NULL
any	NULL
cysteine	NULL
residue	NULL
of	NULL
the	NULL
hRARa-LBD	NULL
had	NULL
no	NULL
significant	NULL
influence	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
all-franrs	NULL
RA	NULL
or	NULL
9-cis	NULL
RA	NULL
.	NULL

Interestingly	NULL
,	NULL
residue	NULL
C-235	NULL
is	NULL
specifically	NULL
important	NULL
in	NULL
antagonist	NULL
binding	NULL
.	NULL

With	NULL
respect	NULL
to	NULL
arginine	NULL
residues	NULL
,	NULL
only	NULL
the	NULL
two	NULL
single	NULL
mutations	NULL
of	NULL
R-276	NULL
and	NULL
R-394	NULL
to	NULL
alanine	NULL
showed	NULL
a	NULL
dramatic	NULL
decrease	NULL
of	NULL
agonist	NULL
and	NULL
antagonist	NULL
binding	NULL
whereas	NULL
the	NULL
R272A	NULL
mutation	NULL
showed	NULL
only	NULL
a	NULL
slight	NULL
effect	NULL
.	NULL

For	NULL
all	NULL
other	NULL
arginine	NULL
mutations	NULL
,	NULL
no	NULL
differences	NULL
in	NULL
affinity	NULL
were	NULL
detectable	NULL
.	NULL

The	NULL
two	NULL
mutations	NULL
R217A	NULL
and	NULL
R294A	NULL
caused	NULL
an	NULL
increased	NULL
binding	NULL
efficiency	NULL
for	NULL
antagonists	NULL
but	NULL
no	NULL
change	NULL
in	NULL
agonist	NULL
binding	NULL
.	NULL

From	NULL
these	NULL
results	NULL
,	NULL
we	NULL
can	NULL
conclude	NULL
that	NULL
electrostatic	NULL
interactions	NULL
of	NULL
retinoids	NULL
with	NULL
the	NULL
RARa	NULL
«	NULL
-LBD	NULL
play	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
ligand	NULL
binding	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
antagonists	NULL
show	NULL
distinctly	NULL
different	NULL
requirements	NULL
for	NULL
efficient	NULL
binding	NULL
,	NULL
which	NULL
may	NULL
contribute	NULL
to	NULL
their	NULL
interference	NULL
in	NULL
the	NULL
ligand-inducible	NULL
trans-	NULL
activation	NULL
function	NULL
of	NULL
RARa	NULL
.	NULL

Retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
is	NULL
a	NULL
biologically	NULL
active	NULL
form	NULL
of	NULL
vitamin	NULL
A.	NULL
All-trans-RA	NULL
(	NULL
t-RA	NULL
)	NULL
has	NULL
effects	NULL
on	NULL
growth	NULL
and	NULL
cell	NULL
differenti-ation	NULL
,	NULL
pattern	NULL
formation	NULL
,	NULL
and	NULL
tumorigenesis	NULL
(	NULL
7	NULL
,	NULL
17	NULL
,	NULL
26-28	NULL
,	NULL
32	NULL
,	NULL
34	NULL
,	NULL
36	NULL
,	NULL
38	NULL
)	NULL
.	NULL

An	NULL
effect	NULL
of	NULL
RA	NULL
on	NULL
nervous	NULL
system	NULL
development	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
(	NULL
15	NULL
,	NULL
40	NULL
,	NULL
41	NULL
)	NULL
.	NULL

The	NULL
discovery	NULL
of	NULL
nuclear	NULL
retinoic	NULL
acid	NULL
receptors	NULL
(	NULL
RARs	NULL
)	NULL
and	NULL
retinoid	NULL
X	NULL
receptors	NULL
(	NULL
RXRs	NULL
)	NULL
has	NULL
greatly	NULL
advanced	NULL
the	NULL
understanding	NULL
of	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
RA	NULL
.	NULL

Three	NULL
subtypes	NULL
(	NULL
«	NULL
,	NULL
B	NULL
,	NULL
and	NULL
y	NULL
)	NULL
constitute	NULL
the	NULL
RAR	NULL
gene	NULL
family	NULL
(	NULL
6	NULL
,	NULL
9	NULL
,	NULL
19	NULL
,	NULL
24	NULL
,	NULL
35	NULL
,	NULL
37	NULL
,	NULL
48	NULL
)	NULL
,	NULL
and	NULL
three	NULL
subtypes	NULL
(	NULL
«	NULL
,	NULL
B	NULL
,	NULL
and	NULL
y	NULL
)	NULL
constitute	NULL
the	NULL
RXR	NULL
family	NULL
(	NULL
22	NULL
,	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

These	NULL
receptors	NULL
belong	NULL
to	NULL
the	NULL
superfamily	NULL
of	NULL
steroid/thyroid	NULL
hormone	NULL
receptors	NULL
and	NULL
are	NULL
in	NULL
fact	NULL
ligand-dependent	NULL
transcrip-tional	NULL
factors	NULL
,	NULL
in	NULL
which	NULL
both	NULL
t-RA	NULL
and	NULL
9-cis-RA	NULL
are	NULL
natural	NULL
ligands	NULL
for	NULL
the	NULL
RARs	NULL
(	NULL
1	NULL
,	NULL
13	NULL
)	NULL
,	NULL
while	NULL
9-cis-RA	NULL
and	NULL
phytanic	NULL
acid	NULL
are	NULL
natural	NULL
ligands	NULL
for	NULL
the	NULL
RXRs	NULL
(	NULL
16	NULL
,	NULL
23	NULL
,	NULL
25	NULL
)	NULL
.	NULL

The	NULL
receptors	NULL
are	NULL
able	NULL
to	NULL
bind	NULL
target	NULL
sequence	NULL
RA	NULL
response	NULL
elements	NULL
(	NULL
RAREs	NULL
)	NULL
for	NULL
RARs	NULL
or	NULL
retinoid	NULL
response	NULL
elements	NULL
(	NULL
RXREs	NULL
)	NULL
for	NULL
RXRs	NULL
(	NULL
12	NULL
,	NULL
31	NULL
)	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
homology	NULL
to	NULL
other	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
,	NULL
the	NULL
primary	NULL
sequences	NULL
of	NULL
RARs	NULL
and	NULL
RXRs	NULL
are	NULL
divided	NULL
into	NULL
distinct	NULL
domains	NULL
designated	NULL
A	NULL
to	NULL
F.	NULL
The	NULL
C	NULL
domain	NULL
constitutes	NULL
the	NULL
highly	NULL
conserved	NULL
DNA-binding	NULL
domain	NULL
,	NULL
and	NULL
the	NULL
E	NULL
domain	NULL
confers	NULL
the	NULL
ligand-binding	NULL
properties	NULL
of	NULL
each	NULL
receptor	NULL
.	NULL

The	NULL
E	NULL
domains	NULL
of	NULL
all	NULL
subtypes	NULL
of	NULL
RARs	NULL
are	NULL
highly	NULL
(	NULL
over	NULL
90	NULL
%	NULL
)	NULL
conserved	NULL
and	NULL
contain	NULL
dimerization	NULL
,	NULL
ligand-binding	NULL
,	NULL
and	NULL
transactivation	NULL
functions	NULL
.	NULL

The	NULL
C-terminal	NULL
part	NULL
of	NULL
the	NULL
D	NULL
domain	NULL
of	NULL
human	NULL
RARa	NULL
(	NULL
hRAR	NULL
«	NULL
)	NULL
is	NULL
also	NULL
required	NULL
for	NULL
ligand	NULL
binding	NULL
,	NULL
while	NULL
the	NULL
F	NULL
domain	NULL
and	NULL
a	NULL
part	NULL
of	NULL
the	NULL
N-terminal	NULL
end	NULL
of	NULL
the	NULL
E	NULL
domain	NULL
can	NULL
be	NULL
deleted	NULL
without	NULL
affecting	NULL
ligand	NULL
binding	NULL
(	NULL
172	NULL
,	NULL
20	NULL
)	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
N-terminal	NULL
portion	NULL
of	NULL
the	NULL
E	NULL
domain	NULL
of	NULL
hRARa	NULL
«	NULL
and	NULL
hRARLB	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
recog-	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
PRPI	NULL
,	NULL
69/11	NULL
,	NULL
F.	NULL
Hoffmann-La	NULL
Roche	NULL
Ltd.	NULL
,	NULL
CH-4070	NULL
Basel	NULL
,	NULL
Switzerland	NULL
.	NULL

Phone	NULL
:	NULL
4161	NULL
688	NULL
5878	NULL
.	NULL

Fax	NULL
:	NULL
4161	NULL
688	NULL
2377	NULL
.	NULL

5386	NULL
nition	NULL
of	NULL
retinoids	NULL
(	NULL
33	NULL
)	NULL
and	NULL
that	NULL
the	NULL
two	NULL
hRARa	NULL
«	NULL
residues	NULL
M-406	NULL
and	NULL
I-410	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
9-cis-RA	NULL
binding	NULL
to	NULL
hRARa	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Experiments	NULL
involving	NULL
limited	NULL
trypsin	NULL
digestion	NULL
of	NULL
RARa	NULL
have	NULL
provided	NULL
evidence	NULL
that	NULL
t-RA	NULL
binding	NULL
to	NULL
the	NULL
hRARa	NULL
ligand-binding	NULL
domain	NULL
(	NULL
LBD	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
9-cis-RA	NULL
binding	NULL
,	NULL
induces	NULL
a	NULL
conformational	NULL
change	NULL
which	NULL
may	NULL
be	NULL
required	NULL
for	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
DNA-bound	NULL
RARa	NULL
«	NULL
-RXRa	NULL
heterodimer	NULL
with	NULL
other	NULL
transcription	NULL
factors	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
RARa	NULL
selective	NULL
antagonist	NULL
Ro	NULL
41-5253	NULL
(	NULL
2	NULL
)	NULL
competes	NULL
with	NULL
agonists	NULL
for	NULL
RARa	NULL
binding	NULL
and	NULL
,	NULL
when	NULL
bound	NULL
to	NULL
the	NULL
receptor	NULL
,	NULL
induces	NULL
a	NULL
different	NULL
conformational	NULL
change	NULL
as	NULL
detected	NULL
by	NULL
limited	NULL
proteolysis	NULL
.	NULL

Sulfhydryl-blocking	NULL
reagents	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
affect	NULL
the	NULL
ligand-binding	NULL
properties	NULL
of	NULL
hRAR	NULL
«	NULL
-LBD	NULL
,	NULL
suggesting	NULL
that	NULL
one	NULL
or	NULL
several	NULL
cysteine	NULL
residues	NULL
of	NULL
the	NULL
E	NULL
domain	NULL
could	NULL
be	NULL
relevant	NULL
for	NULL
the	NULL
interaction	NULL
between	NULL
t-RA	NULL
and	NULL
hRARa	NULL
«	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
a	NULL
free	NULL
carboxyl	NULL
group	NULL
on	NULL
retinoids	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
ligand	NULL
binding	NULL
to	NULL
RARs	NULL
(	NULL
3	NULL
,	NULL
21	NULL
)	NULL
.	NULL

The	NULL
hypothesis	NULL
that	NULL
basic	NULL
amino	NULL
acids	NULL
such	NULL
as	NULL
arginine	NULL
or	NULL
lysine	NULL
are	NULL
involved	NULL
in	NULL
ligand-receptor	NULL
binding	NULL
has	NULL
been	NULL
recently	NULL
confirmed	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
R-269	NULL
and	NULL
K-220	NULL
of	NULL
RARB	NULL
are	NULL
important	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
RA	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
R-132	NULL
of	NULL
cytoplasmic	NULL
RA-binding	NULL
protein	NULL
II	NULL
was	NULL
found	NULL
to	NULL
be	NULL
implicated	NULL
in	NULL
the	NULL
t-RA	NULL
binding	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
cocrystal	NULL
hRARy-t-RA	NULL
has	NULL
been	NULL
determined	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Three	NULL
arginine	NULL
residues	NULL
(	NULL
R-274	NULL
,	NULL
R-278	NULL
,	NULL
and	NULL
R-396	NULL
)	NULL
and	NULL
one	NULL
lysine	NULL
residue	NULL
(	NULL
K-236	NULL
)	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
ligand-binding	NULL
pocket	NULL
of	NULL
hRARy	NULL
.	NULL

To	NULL
further	NULL
clarify	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
LBD	NULL
of	NULL
hRARa	NULL
with	NULL
t-RA	NULL
,	NULL
9-cis-RA	NULL
,	NULL
and	NULL
other	NULL
agonists	NULL
and	NULL
antagonists	NULL
,	NULL
we	NULL
have	NULL
prepared	NULL
site-specific	NULL
mutants	NULL
of	NULL
the	NULL
hRAR	NULL
«	NULL
-LBD	NULL
.	NULL

We	NULL
have	NULL
characterized	NULL
these	NULL
mutants	NULL
by	NULL
using	NULL
blocking	NULL
reactions	NULL
,	NULL
ligand-binding	NULL
experiments	NULL
,	NULL
transactivation	NULL
assays	NULL
,	NULL
and	NULL
protease	NULL
mapping	NULL
.	NULL

We	NULL
have	NULL
come	NULL
to	NULL
the	NULL
conclusion	NULL
that	NULL
the	NULL
cysteine	NULL
residues	NULL
of	NULL
the	NULL
hRARa-LBD	NULL
play	NULL
no	NULL
direct	NULL
role	NULL
in	NULL
the	NULL
ligand-receptor	NULL
interaction	NULL
whereas	NULL
two	NULL
single	NULL
arginine	NULL
residues	NULL
,	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
SITE-DIRECTED	NULL
MUTAGENESIS	NULL
OF	NULL
hRARa	NULL
5387	NULL
H1	NULL
209	NULL
156	NULL
E	NULL
5	NULL
V	NULL
R	NULL
N	NULL
D	NULL
RN	NULL
K	NULL
K	NULL
KOK	NULL
EV	NULL
OPK	NULL
OP	NULL
ECG	NULL
ES	NULL
YTL'TPEYVG	NULL
ELIEKVRKAH	NULL
Q	NULL
ET	NULL
FPA	NULL
LICIQ	NULL
L	NULL
hRARe	NULL
149	NULL
E	NULL
5	NULL
Y	NULL
RN	NULL
D	NULL
RN	NULL
K	NULL
K	NULL
Kok	NULL
E	NULL
T	NULL
S	NULL
K	NULL
Q	NULL
EC	NULL
T	NULL
ES	NULL
¥	NULL
Em	NULL
T	NULL
A	NULL
EL	NULL
O	NULL
DL	NULL
T	NULL
EX	NULL
I	NULL
R	NULL
KA	NULL
H	NULL
Q	NULL
ET	NULL
FOP	NULL
S	NULL
L	NULL
hRARB	NULL
158	NULL
E	NULL
A	NULL
V	NULL
RN	NULL
D	NULL
RON	NULL
K	NULL
K	NULL
KOK	NULL
EV	NULL
K	NULL
E	NULL
E	NULL
G	NULL
S	NULL
P	NULL
D	NULL
S	NULL
Y	NULL
E	NULL
L	NULL
,	NULL
§	NULL
PQ	NULL
L	NULL
B	NULL
BL	NULL
I	NULL
T	NULL
K	NULL
Y	NULL
5	NULL
KA	NULL
H	NULL
Q	NULL
E	NULL
[	NULL
,	NULL
F	NULL
PS	NULL
LIC	NULL
QL	NULL
hRARy	NULL
217	NULL
3	NULL
s	NULL
206	NULL
G	NULL
KY	NULL
T	NULL
T	NULL
N	NULL
N	NULL
S	NULL
S	NULL
E	NULL
QVSLD'IDLWD	NULL
FS	NULL
EL	NULL
S	NULL
T	NULL
K	NULL
I	NULL
KTVEFAFQ	NULL
LOB	NULL
G	NULL
FT	NULL
T	NULL
L	NULL
T	NULL
1	NULL
&	NULL
a	NULL
hRéfa	NULL
199	NULL
G	NULL
K	NULL
Y	NULL
T	NULL
T	NULL
N	NULL
S	NULL
5	NULL
A	NULL
D	NULL
HVR	NULL
L	NULL
D	NULL
L	NULL
GL	NULL
W	NULL
D	NULL
KOF	NULL
5	NULL
EL	NULL
A	NULL
T	NULL
K	NULL
I	NULL
I	NULL
K	NULL
IV	NULL
E	NULL
F	NULL
A	NULL
KR	NULL
LPG	NULL
FT	NULL
GL	NULL
T	NULL
I	NULL
A	NULL
hRARG	NULL
208	NULL
G	NULL
K	NULL
¥	NULL
T	NULL
TNS	NULL
S	NULL
a	NULL
b	NULL
HIV	NULL
QL	NULL
D.L	NULL
GL	NULL
W	NULL
O	NULL
KF	NULL
S	NULL
EL	NULL
A	NULL
T	NULL
K	NULL
I	NULL
I	NULL
K	NULL
IV	NULL
E	NULL
F	NULL
A	NULL
KR	NULL
L	NULL
P	NULL
G	NULL
F	NULL
T	NULL
G	NULL
I	NULL
A	NULL
hRARy	NULL
H4	NULL
285	NULL
HS	NULL
me	NULL
om	NULL
|	NULL
2m	NULL
aga	NULL
__	NULL
H6	NULL
ZSGDQITLLKAHAC	NULL
L	NULL
bILILRIICT	NULL
y	NULL
TPEQDT	NULL
MT	NULL
F5	NULL
DGLTLNGT	NULL
GMH	NULL
NA	NULL
GE	NULL
GPL	NULL
hRARe	NULL
249	NULL
DQ	NULL
I	NULL
T	NULL
L	NULL
L	NULL
K	NULL
A	NULL
AJC|	NULL
L	NULL
D	NULL
IL	NULL
I	NULL
[	NULL
YT	NULL
PEQDTMT	NULL
FS	NULL
D	NULL
G	NULL
L	NULL
TL	NULL
NT	NULL
Q	NULL
M	NULL
HON	NULL
A	NULL
G	NULL
F	NULL
G	NULL
P	NULL
L	NULL
hRARG	NULL
258	NULL
D	NULL
Q	NULL
I	NULL
T	NULL
L	NULL
L	NULL
K	NULL
AAJC	NULL
)	NULL
L	NULL
D	NULL
I	NULL
L	NULL
M	NULL
@	NULL
TIICIT	NULL
,	NULL
[	NULL
gv	NULL
T	NULL
REQ	NULL
DT	NULL
M	NULL
T	NULL
OF	NULL
5	NULL
D	NULL
G	NULL
L	NULL
T	NULL
L	NULL
NIT	NULL
G	NULL
MH	NULL
NA	NULL
G	NULL
F	NULL
G	NULL
P	NULL
L-	NULL
hRARy	NULL
H7	NULL
H8	NULL
3s	NULL
26	NULL
aso	NULL
aar	NULL
Hg	NULL
sage	NULL
T	NULL
DL	NULL
v	NULL
Fa	NULL
F	NULL
Am	NULL
q	NULL
L1	NULL
Pl	NULL
Eko	NULL
oa	NULL
e	NULL
toll	NULL
$	NULL
ag	NULL
[	NULL
Gi't	NULL
[	NULL
C6	NULL
0Gq	NULL
ole	NULL
qr	NULL
0	NULL
RV	NULL
DM	NULL
L	NULL
Q	NULL
EP	NULL
L	NULL
hRAks	NULL
299	NULL
T	NULL
D	NULL
L	NULL
V	NULL
F	NULL
T	NULL
F	NULL
A	NULL
NQ	NULL
LLP	NULL
L	NULL
EM	NULL
D	NULL
D	NULL
T	NULL
E	NULL
TGL	NULL
L	NULL
S	NULL
A	NULL
IJCIL	NULL
I	NULL
DBQ	NULL
D	NULL
L	NULL
E	NULL
EP	NULL
T	NULL
KV	NULL
D	NULL
KL	NULL
Q	NULL
E	NULL
P	NULL
L	NULL
hRARK	NULL
308	NULL
I	NULL
D	NULL
L	NULL
Y	NULL
F	NULL
A	NULL
FA	NULL
GQ	NULL
LL	NULL
EM	NULL
T	NULL
E	NULL
TGLLSAIIGL	NULL
,	NULL
EI	NULL
[	NULL
G6	NULL
0m	NULL
pL	NULL
E	NULL
fir	NULL
&	NULL
kv	NULL
0	NULL
kL	NULL
GE	NULL
PG	NULL
hRARy	NULL
sa	NULL
ase	NULL
ser	NULL
-	NULL
370	NULL
H10	NULL
385	NULL
aas	NULL
__H11	NULL
356	NULL
L	NULL
E	NULL
AL	NULL
KV	NULL
Y	NULL
V	NULL
[	NULL
RIK	NULL
[	NULL
R	NULL
[	NULL
RPS	NULL
RP	NULL
HM	NULL
FP	NULL
KML	NULL
M	NULL
K	NULL
I	NULL
T	NULL
D	NULL
LR	NULL
]	NULL
S	NULL
I	NULL
S	NULL
A	NULL
K	NULL
'	NULL
G	NULL
a	NULL
EV	NULL
I	NULL
T	NULL
L	NULL
KM	NULL
EI	NULL
P	NULL
G	NULL
S	NULL
hRARG	NULL
349	NULL
LOE	NULL
A	NULL
L	NULL
K	NULL
I	NULL
Y	NULL
I/RLK	NULL
RPSKPHMFP	NULL
K	NULL
I	NULL
L	NULL
MK	NULL
I	NULL
T	NULL
D	NULL
SISAKGAEEV	NULL
I	NULL
T	NULL
L	NULL
K	NULL
M	NULL
E	NULL
I	NULL
P	NULL
G	NULL
5	NULL
hRARS	NULL
B58	NULL
LOE	NULL
A	NULL
L	NULL
RL	NULL
Y	NULL
A	NULL
[	NULL
RIR	NULL
[	NULL
RJRIR	NULL
S	NULL
QP	NULL
Y	NULL
,	NULL
.M	NULL
F	NULL
P	NULL
ROM	NULL
L	NULL
M	NULL
K	NULL
I	NULL
T	NULL
B	NULL
LIBR	NULL
]	NULL
G	NULL
T	NULL
S	NULL
T	NULL
K6	NULL
A	NULL
E	NULL
[	NULL
@	NULL
A	NULL
_I	NULL
T	NULL
L	NULL
K	NULL
M	NULL
E	NULL
,	NULL
I	NULL
P	NULL
?	NULL

G	NULL
P	NULL
hRARYy	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Alignment	NULL
of	NULL
the	NULL
LBD	NULL
of	NULL
hRARa	NULL
,	NULL
hRAR	NULL
$	NULL
B	NULL
,	NULL
and	NULL
hRARy	NULL
.	NULL

All	NULL
mutated	NULL
cysteines	NULL
and	NULL
arginines	NULL
are	NULL
boxed	NULL
.	NULL

Mutations	NULL
which	NULL
showed	NULL
a	NULL
weak	NULL
effect	NULL
are	NULL
indicated	NULL
by	NULL
an	NULL
open	NULL
box	NULL
,	NULL
and	NULL
mutations	NULL
with	NULL
a	NULL
strong	NULL
effect	NULL
are	NULL
indicated	NULL
by	NULL
a	NULL
solid	NULL
box	NULL
.	NULL

R-394	NULL
and	NULL
R-276	NULL
,	NULL
do	NULL
play	NULL
a	NULL
significant	NULL
role	NULL
,	NULL
since	NULL
mutations	NULL
into	NULL
alanine	NULL
at	NULL
these	NULL
residues	NULL
led	NULL
to	NULL
a	NULL
dramatic	NULL
decrease	NULL
in	NULL
ligand	NULL
binding	NULL
.	NULL

The	NULL
same	NULL
influence	NULL
of	NULL
these	NULL
mutations	NULL
was	NULL
observed	NULL
for	NULL
t-RA	NULL
,	NULL
9-cis-RA	NULL
,	NULL
and	NULL
synthetic	NULL
retinoids	NULL
(	NULL
agonists	NULL
and	NULL
antagonists	NULL
)	NULL
.	NULL

The	NULL
mutations	NULL
R217A	NULL
and	NULL
R294A	NULL
increase	NULL
the	NULL
ability	NULL
of	NULL
hRARa	NULL
«	NULL
to	NULL
bind	NULL
antagonists	NULL
,	NULL
while	NULL
the	NULL
mutation	NULL
C235G	NULL
specifically	NULL
decreases	NULL
antagonist	NULL
binding	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Materials	NULL
.	NULL

t-RA	NULL
,	NULL
9-cis-RA	NULL
,	NULL
and	NULL
synthetic	NULL
retinoids	NULL
were	NULL
synthesized	NULL
at	NULL
F.	NULL
Hoffmann-La	NULL
Roche	NULL
Ltd.	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
.	NULL

t-	NULL
[	NULL
PHJRA	NULL
(	NULL
53.9	NULL
Ci/mmol	NULL
;	NULL
1	NULL
mCi/	NULL
ml	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
DuPont/NEN	NULL
.	NULL

9-cis-	NULL
[	NULL
°HJRA	NULL
(	NULL
47	NULL
Ci/mmol	NULL
;	NULL
0.2	NULL
mCi/ml	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Amersham	NULL
.	NULL

The	NULL
retinoids	NULL
were	NULL
solubilized	NULL
in	NULL
dimethyl	NULL
sul-foxide	NULL
as	NULL
10	NULL
mM	NULL
stock	NULL
solutions	NULL
and	NULL
kept	NULL
at	NULL
-20°C	NULL
.	NULL

The	NULL
blocking	NULL
reagents	NULL
2,3-butanedione	NULL
,	NULL
N-ethylmaleimide	NULL
,	NULL
and	NULL
5,5'-dithiobis	NULL
(	NULL
2-nitrobenzoic	NULL
acid	NULL
)	NULL
(	NULL
DTNB	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Fluka	NULL
.	NULL

Sequencing	NULL
reactions	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
Sequenase	NULL
plasmid-sequencing	NULL
kit	NULL
(	NULL
U.S.	NULL
Biochemicals	NULL
)	NULL
,	NULL
and	NULL
«	NULL
-*°S-dATP	NULL
(	NULL
1	NULL
mCi	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Amersham	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
transcription-translation	NULL
reactions	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
TNT	NULL
coupled	NULL
reticulocyte	NULL
lysate	NULL
system	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
.	NULL

The	NULL
method	NULL
used	NULL
here	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
5	NULL
)	NULL
.	NULL

All	NULL
mutants	NULL
were	NULL
produced	NULL
by	NULL
two	NULL
PCRs	NULL
,	NULL
the	NULL
second	NULL
one	NULL
consisting	NULL
of	NULL
two	NULL
steps	NULL
.	NULL

The	NULL
first	NULL
PCR	NULL
product	NULL
was	NULL
obtained	NULL
with	NULL
a	NULL
5	NULL
'	NULL
mutagenic	NULL
primer	NULL
and	NULL
3	NULL
'	NULL
primer	NULL
(	NULL
positions	NULL
1389	NULL
to	NULL
1369	NULL
)	NULL
on	NULL
plasmid	NULL
DNA	NULL
containing	NULL
hRARe-LBD	NULL
(	NULL
positions	NULL
466	NULL
to	NULL
1389	NULL
)	NULL
as	NULL
the	NULL
template	NULL
.	NULL

The	NULL
amplified	NULL
fragment	NULL
was	NULL
eluted	NULL
from	NULL
an	NULL
agarose	NULL
gel	NULL
.	NULL

Together	NULL
with	NULL
a	NULL
5	NULL
'	NULL
primer	NULL
(	NULL
positions	NULL
466	NULL
to	NULL
486	NULL
)	NULL
,	NULL
this	NULL
first	NULL
PCR	NULL
fragment	NULL
was	NULL
used	NULL
in	NULL
the	NULL
second	NULL
PCR	NULL
as	NULL
a	NULL
3	NULL
'	NULL
megaprimer	NULL
,	NULL
and	NULL
a	NULL
complete	NULL
hRARa-LBD	NULL
was	NULL
obtained	NULL
after	NULL
11	NULL
cycles	NULL
with	NULL
the	NULL
now	NULL
3'-truncated	NULL
hRARa	NULL
(	NULL
positions	NULL
1	NULL
to	NULL
1305	NULL
)	NULL
as	NULL
template	NULL
.	NULL

To	NULL
increase	NULL
the	NULL
yield	NULL
of	NULL
mutagenic	NULL
hRARa-LBD	NULL
,	NULL
the	NULL
3	NULL
'	NULL
primer	NULL
(	NULL
positions	NULL
1389	NULL
to	NULL
1369	NULL
)	NULL
was	NULL
added	NULL
for	NULL
the	NULL
last	NULL
16	NULL
cycles	NULL
.	NULL

The	NULL
fragment	NULL
was	NULL
cleaved	NULL
with	NULL
EcoRI	NULL
and	NULL
BamHI	NULL
(	NULL
located	NULL
in	NULL
the	NULL
5	NULL
'	NULL
primer	NULL
and	NULL
the	NULL
3	NULL
'	NULL
primer	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
purified	NULL
from	NULL
an	NULL
agarose	NULL
gel	NULL
,	NULL
and	NULL
cloned	NULL
in	NULL
T7	NULL
Escherichia	NULL
coli	NULL
expression	NULL
vector	NULL
pET-3a	NULL
(	NULL
44	NULL
)	NULL
in	NULL
which	NULL
the	NULL
original	NULL
EcoRI	NULL
site	NULL
was	NULL
destroyed	NULL
and	NULL
a	NULL
new	NULL
EcoRI	NULL
site	NULL
was	NULL
inserted	NULL
directly	NULL
after	NULL
the	NULL
ATG	NULL
of	NULL
the	NULL
Nde	NULL
!	NULL

site	NULL
.	NULL

For	NULL
all	NULL
clones	NULL
,	NULL
the	NULL
correctness	NULL
of	NULL
the	NULL
sequence	NULL
was	NULL
confirmed	NULL
by	NULL
sequencing	NULL
.	NULL

The	NULL
efficiency	NULL
of	NULL
the	NULL
mutagenesis	NULL
observed	NULL
was	NULL
between	NULL
65	NULL
and	NULL
100	NULL
%	NULL
.	NULL

Binding	NULL
assay	NULL
and	NULL
K	NULL
,	NULL
,	NULL
and	NULL
IC	NULL
,	NULL
,	NULL
determination	NULL
.	NULL

Mutated	NULL
and	NULL
wild-type	NULL
(	NULL
wt	NULL
)	NULL
hRARa-LBD	NULL
were	NULL
expressed	NULL
in	NULL
£	NULL
.	NULL

coli	NULL
BL21	NULL
(	NULL
DE3	NULL
)	NULL
/pLysS	NULL
(	NULL
44	NULL
)	NULL
,	NULL
after	NULL
isopropyl-B-p-thiogalactopyranoside	NULL
(	NULL
IPTG	NULL
)	NULL
induction	NULL
.	NULL

The	NULL
protein	NULL
extractions	NULL
were	NULL
performed	NULL
from	NULL
250-ml	NULL
cultures	NULL
by	NULL
lysis	NULL
of	NULL
the	NULL
cells	NULL
washed	NULL
in	NULL
50	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
-30	NULL
uM	NULL
dithiothreitol	NULL
.	NULL

After	NULL
centrifugation	NULL
for	NULL
10	NULL
min	NULL
at	NULL
3,400	NULL
X	NULL
g	NULL
and	NULL
4°C	NULL
,	NULL
the	NULL
bacteria	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
on	NULL
ice	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
[	NULL
pH	NULL
8.0	NULL
]	NULL
,	NULL
10	NULL
mM	NULL
EDTA	NULL
[	NULL
pH	NULL
8.0	NULL
]	NULL
,	NULL
75	NULL
mM	NULL
glucose	NULL
,	NULL
2	NULL
mM	NULL
dithiothreitol	NULL
)	NULL
together	NULL
with	NULL
2	NULL
mg	NULL
of	NULL
lysozyme	NULL
per	NULL
ml	NULL
;	NULL
100	NULL
mM	NULL
NaCl	NULL
and	NULL
2	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
were	NULL
then	NULL
added	NULL
(	NULL
final	NULL
concentration	NULL
)	NULL
,	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
freeze-thawed	NULL
twice	NULL
.	NULL

After	NULL
addition	NULL
of	NULL
0.15	NULL
U	NULL
of	NULL
aprotinin	NULL
and	NULL
20	NULL
pg	NULL
of	NULL
leupeptin	NULL
per	NULL
ml	NULL
(	NULL
final	NULL
concentration	NULL
)	NULL
,	NULL
the	NULL
samples	NULL
were	NULL
sonicated	NULL
on	NULL
ice	NULL
four	NULL
times	NULL
for	NULL
30	NULL
s	NULL
at	NULL
level	NULL
3	NULL
to	NULL
4	NULL
with	NULL
a	NULL
Branson	NULL
Sonifier	NULL
250	NULL
.	NULL

After	NULL
centrifugation	NULL
for	NULL
10	NULL
min	NULL
at	NULL
24,000	NULL
X	NULL
g	NULL
and	NULL
4°C	NULL
,	NULL
the	NULL
supernatant	NULL
was	NULL
recovered	NULL
.	NULL

The	NULL
protein	NULL
concentration	NULL
was	NULL
determined	NULL
by	NULL
a	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
,	NULL
and	NULL
15	NULL
ug	NULL
of	NULL
total	NULL
protein	NULL
was	NULL
loaded	NULL
on	NULL
a	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
-10	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
to	NULL
verify	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
expressed	NULL
hRARa-LBD	NULL
in	NULL
the	NULL
crude	NULL
protein	NULL
extracts	NULL
.	NULL

For	NULL
each	NULL
protein	NULL
extract	NULL
,	NULL
a	NULL
series	NULL
of	NULL
dilutions	NULL
were	NULL
made	NULL
and	NULL
used	NULL
in	NULL
binding	NULL
assays	NULL
to	NULL
define	NULL
the	NULL
appropriate	NULL
amount	NULL
of	NULL
extract	NULL
to	NULL
use	NULL
for	NULL
the	NULL
50	NULL
%	NULL
inhibitory	NULL
concentration	NULL
(	NULL
ICs	NULL
,	NULL
)	NULL
and	NULL
K	NULL
,	NULL
,	NULL
determinations	NULL
.	NULL

The	NULL
binding	NULL
assay	NULL
and	NULL
the	NULL
calculation	NULL
of	NULL
the	NULL
ICs	NULL
,	NULL
were	NULL
done	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Scatchard	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Scatchard	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Transactivation	NULL
assay	NULL
.	NULL

For	NULL
construction	NULL
of	NULL
an	NULL
RARa	NULL
expression	NULL
vector	NULL
for	NULL
eukaryotic	NULL
cells	NULL
and	NULL
for	NULL
in	NULL
vitro	NULL
translation	NULL
(	NULL
see	NULL
below	NULL
)	NULL
,	NULL
the	NULL
N-terminal	NULL
part	NULL
of	NULL
hRARa	NULL
(	NULL
positions	NULL
1	NULL
to	NULL
465	NULL
)	NULL
was	NULL
cloned	NULL
into	NULL
pSGS	NULL
(	NULL
14	NULL
)	NULL
.	NULL

For	NULL
this	NULL
,	NULL
the	NULL
EcoRI-BamHI	NULL
fragment	NULL
of	NULL
pSGS	NULL
was	NULL
replaced	NULL
by	NULL
a	NULL
linker	NULL
containing	NULL
MscI	NULL
,	NULL
EcoRI	NULL
,	NULL
and	NULL
BamHI	NULL
sites	NULL
(	NULL
5'-AATTGCCACCATGGCCAGACGAATTCTCAGGATC-3	NULL
'	NULL
)	NULL
and	NULL
cleaved	NULL
with	NULL
Mscl	NULL
and	NULL
EcoRI	NULL
,	NULL
and	NULL
a	NULL
Mscl-EcoRI	NULL
PCR	NULL
product	NULL
corresponding	NULL
to	NULL
hRARa	NULL
(	NULL
positions	NULL
1	NULL
to	NULL
465	NULL
)	NULL
was	NULL
inserted	NULL
.	NULL

The	NULL
correctness	NULL
of	NULL
the	NULL
sequence	NULL
was	NULL
confirmed	NULL
by	NULL
sequencing	NULL
.	NULL

In	NULL
a	NULL
second	NULL
step	NULL
,	NULL
the	NULL
C-terminal	NULL
part	NULL
of	NULL
RARa	NULL
(	NULL
wt	NULL
or	NULL
mutated	NULL
form	NULL
)	NULL
was	NULL
inserted	NULL
as	NULL
an	NULL
EcoRI-BamHI	NULL
fragment	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
full-length	NULL
receptor	NULL
with	NULL
mutants	NULL
at	NULL
each	NULL
cysteine	NULL
or	NULL
arginine	NULL
in	NULL
the	NULL
E	NULL
domain	NULL
.	NULL

The	NULL
modification	NULL
of	NULL
the	NULL
first	NULL
two	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
D	NULL
domain	NULL
due	NULL
to	NULL
the	NULL
insertion	NULL
of	NULL
the	NULL
EcoRI	NULL
cloning	NULL
site	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
transactivation	NULL
efficiency	NULL
,	NULL
and	NULL
we	NULL
observed	NULL
the	NULL
same	NULL
50	NULL
%	NULL
effective	NULL
concentration	NULL
(	NULL
EC	NULL
,	NULL
,	NULL
)	NULL
for	NULL
the	NULL
last	NULL
construct	NULL
in	NULL
as	NULL
that	NULL
for	NULL
the	NULL
wt	NULL
hRARa	NULL
.	NULL

The	NULL
RAR	NULL
reporter	NULL
plasmid	NULL
used	NULL
in	NULL
transactivation	NULL
assays	NULL
was	NULL
constructed	NULL
with	NULL
a	NULL
synthetic	NULL
oligonucleotide	NULL
containing	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
RAR	NULL
response	NULL
element	NULL
from	NULL
the	NULL
RARB	NULL
promoter	NULL
(	NULL
12	NULL
)	NULL
in	NULL
front	NULL
of	NULL
the	NULL
basal	NULL
promoter	NULL
of	NULL
thymidine	NULL
kinase	NULL
and	NULL
the	NULL
luciferase	NULL
coding	NULL
region	NULL
in	NULL
the	NULL
plasmid	NULL
pGL2-basic	NULL
(	NULL
Promega	NULL
)	NULL
BRARE-thymidine	NULL
kinase-luciferase	NULL
.	NULL

The	NULL
transfection	NULL
was	NULL
performed	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
coprecipitation	NULL
method	NULL
(	NULL
42	NULL
)	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
as	NULL
described	NULL
previously	NULL
for	NULL
COS	NULL
cells	NULL
(	NULL
4	NULL
)	NULL
.	NULL

After	NULL
addition	NULL
of	NULL
t-RA	NULL
or	NULL
Ro	NULL
13-7410	NULL
and	NULL
incubation	NULL
for	NULL
36	NULL
h	NULL
,	NULL
the	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
and	NULL
the	NULL
ECs	NULL
,	NULL
was	NULL
calculated	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
,	NULL
translation	NULL
,	NULL
and	NULL
limited	NULL
proteolytic	NULL
digestion	NULL
.	NULL

Human	NULL
RARa	NULL
(	NULL
wt	NULL
or	NULL
mutated	NULL
)	NULL
in	NULL
pSGS	NULL
was	NULL
transcribed	NULL
and	NULL
in	NULL
vitro	NULL
translated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
by	NULL
using	NULL
rabbit	NULL
reticulocyte	NULL
lysates	NULL
as	NULL
specified	NULL
by	NULL
Promega	NULL
.	NULL

The	NULL
limited	NULL
proteolytic	NULL
digestions	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
18	NULL
)	NULL
.	NULL

RESULTS	NULL
Cysteine	NULL
point	NULL
mutations	NULL
in	NULL
the	NULL
E	NULL
domain	NULL
of	NULL
hRARa	NULL
«	NULL
.	NULL

From	NULL
the	NULL
results	NULL
of	NULL
blocking	NULL
reactions	NULL
with	NULL
cysteine-specific	NULL
reagents	NULL
,	NULL
it	NULL
has	NULL
been	NULL
previously	NULL
postulated	NULL
that	NULL
one	NULL
or	NULL
several	NULL
sulfhydryls	NULL
are	NULL
involved	NULL
in	NULL
ligand-hRAR	NULL
«	NULL
interactions	NULL
(	NULL
11	NULL
)	NULL
.	NULL

We	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
N-ethylmaleimide	NULL
and	NULL
DTNB	NULL
on	NULL
t-RA	NULL
binding	NULL
with	NULL
wt	NULL
hRARa-LBD	NULL
.	NULL

We	NULL
found	NULL
the	NULL
same	NULL
effect	NULL
of	NULL
t-RA	NULL
on	NULL
the	NULL
wt	NULL
receptor	NULL
,	NULL
consisting	NULL
of	NULL
a	NULL
decrease	NULL
in	NULL
binding	NULL
when	NULL
increasing	NULL
amounts	NULL
of	NULL
blocking	NULL
reagent	NULL
were	NULL
used	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
K	NULL
,	NULL
,	NULL
determination	NULL
of	NULL
wt	NULL
hRAR	NULL
«	NULL
-LBD	NULL
resulted	NULL
in	NULL
a	NULL
value	NULL
of	NULL
0.6	NULL
nM	NULL
for	NULL
t-	NULL
RA	NULL
,	NULL
which	NULL
establishes	NULL
the	NULL
functionality	NULL
of	NULL
the	NULL
procaryotic	NULL
expression	NULL
and	NULL
extraction	NULL
methods	NULL
.	NULL

The	NULL
K	NULL
,	NULL
,	NULL
correlates	NULL
well	NULL
with	NULL
that	NULL
determined	NULL
previously	NULL
for	NULL
the	NULL
full-length	NULL
receptor	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Each	NULL
cysteine	NULL
residue	NULL
in	NULL
the	NULL
LBD	NULL
of	NULL
hRARa	NULL
has	NULL
been	NULL
changed	NULL
to	NULL
glycine	NULL
(	NULL
C-203	NULL
,	NULL
C-235	NULL
,	NULL
C-274	NULL
,	NULL
C-333	NULL
,	NULL
and	NULL
C-336	NULL
[	NULL
an	NULL
overview	NULL
is	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
]	NULL
)	NULL
.	NULL

Only	NULL
the	NULL
single	NULL
C265G	NULL
change	NULL
showed	NULL
a	NULL
decrease	NULL
of	NULL
binding	NULL
(	NULL
15-fold	NULL
for	NULL
t-RA	NULL
and	NULL
95-fold	NULL
for	NULL
9-cis-RA	NULL
)	NULL
as	NULL
determined	NULL
by	NULL
Scatchard	NULL
analysis	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

C-265	NULL
has	NULL
also	NULL
been	NULL
changed	NULL
to	NULL
alanine	NULL
.	NULL

This	NULL
mutated	NULL
receptor	NULL
showed	NULL
an	NULL
IC	NULL
,	NULL
,	NULL
of	NULL
6	NULL
nM	NULL
and	NULL
an	NULL
5388	NULL
LAMOUR	NULL
ET	NULL
AL	NULL
.	NULL

TABLE	NULL
1.	NULL
t-RA-	NULL
and	NULL
9-cis-RA-binding	NULL
properties	NULL
of	NULL
wt	NULL
hRARa-LBD	NULL
and	NULL
selected	NULL
mutants	NULL
Binding	NULL
Activity	NULL
Chemical	NULL
structure	NULL
hRARKc-LBD	NULL
K	NULL
,	NULL
,	NULL
(	NULL
nMy	NULL
)	NULL
2	NULL
wt	NULL
11.6	NULL
©€265G	NULL
9.3	NULL
R217G	NULL
37	NULL
R272G	NULL
71	NULL
R276G	NULL
20	NULL
Rz94G	NULL
34	NULL
R339YG	NULL
28	NULL
R394G	NULL
ndb	NULL
wt	NULL
1.2	NULL
C265G	NULL
115	NULL
R217G	NULL
48	NULL
R272G	NULL
58	NULL
R27	NULL
&	NULL
G	NULL
93	NULL
R294G	NULL
15	NULL
R339G	NULL
8.1	NULL
R394G	NULL
rude	NULL
``	NULL
The	NULL
K	NULL
;	NULL
,	NULL
values	NULL
were	NULL
obtained	NULL
by	NULL
Scatchard	NULL
analysis	NULL
.	NULL

The	NULL
K	NULL
;	NULL
,	NULL
values	NULL
and	NULL
ICs	NULL
,	NULL
are	NULL
the	NULL
means	NULL
of	NULL
two	NULL
single	NULL
experiments	NULL
.	NULL

*	NULL
n.d.	NULL
,	NULL
not	NULL
determined	NULL
because	NULL
of	NULL
low	NULL
binding	NULL
activity	NULL
.	NULL

ECs	NULL
,	NULL
of	NULL
15	NULL
nM	NULL
for	NULL
t-RA	NULL
in	NULL
binding	NULL
and	NULL
transactivation	NULL
experiments	NULL
,	NULL
thus	NULL
showing	NULL
no	NULL
difference	NULL
from	NULL
the	NULL
wt	NULL
.	NULL

For	NULL
the	NULL
double	NULL
mutant	NULL
hRARa	NULL
«	NULL
-C265G/C274G	NULL
,	NULL
a	NULL
K	NULL
,	NULL
,	NULL
of	NULL
120	NULL
nM	NULL
has	NULL
been	NULL
obtained	NULL
for	NULL
t-RA	NULL
,	NULL
which	NULL
is	NULL
200-fold	NULL
higher	NULL
than	NULL
for	NULL
the	NULL
wt	NULL
.	NULL

The	NULL
double	NULL
mutant	NULL
hRAR	NULL
«	NULL
-C333G/C336G	NULL
did	NULL
not	NULL
show	NULL
any	NULL
difference	NULL
from	NULL
the	NULL
wt	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
the	NULL
same	NULL
tendency	NULL
was	NULL
observed	NULL
when	NULL
9-cis-RA	NULL
or	NULL
synthetic	NULL
agonists	NULL
were	NULL
used	NULL
as	NULL
ligands	NULL
in	NULL
the	NULL
binding	NULL
assays	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Role	NULL
of	NULL
hRARa	NULL
«	NULL
C-235	NULL
in	NULL
ligand	NULL
binding	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
mutant	NULL
C235G	NULL
showed	NULL
a	NULL
dramatic	NULL
reduction	NULL
in	NULL
binding	NULL
for	NULL
all	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

antagonists	NULL
that	NULL
have	NULL
been	NULL
tested	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

The	NULL
analogs	NULL
Ro	NULL
41-5253	NULL
,	NULL
Ro	NULL
46-5471	NULL
,	NULL
and	NULL
Ro	NULL
46-6464	NULL
all	NULL
indicate	NULL
a	NULL
role	NULL
for	NULL
C-235	NULL
of	NULL
hRARa-LBD	NULL
in	NULL
antagonist	NULL
interaction	NULL
.	NULL

Ro	NULL
41-5253	NULL
,	NULL
which	NULL
has	NULL
a	NULL
phenyl	NULL
group	NULL
in	NULL
the	NULL
upper	NULL
side	NULL
chain	NULL
,	NULL
exhibited	NULL
a	NULL
60-fold	NULL
higher	NULL
IC	NULL
,	NULL
,	NULL
for	NULL
the	NULL
mutant	NULL
C235G	NULL
than	NULL
the	NULL
wt	NULL
.	NULL

In	NULL
the	NULL
other	NULL
antagonists	NULL
,	NULL
changing	NULL
from	NULL
a	NULL
six-	NULL
to	NULL
a	NULL
seven-membered	NULL
carbon	NULL
ring	NULL
(	NULL
Ro	NULL
46-6464	NULL
)	NULL
or	NULL
removing	NULL
the	NULL
upper	NULL
side	NULL
chain	NULL
phenyl	NULL
group	NULL
(	NULL
Ro	NULL
46-5471	NULL
)	NULL
,	NULL
also	NULL
resulted	NULL
in	NULL
a	NULL
lower	NULL
binding	NULL
efficiency	NULL
(	NULL
about	NULL
10-fold	NULL
lower	NULL
than	NULL
the	NULL
wt	NULL
)	NULL
.	NULL

The	NULL
use	NULL
of	NULL
other	NULL
antagonists	NULL
,	NULL
in	NULL
which	NULL
the	NULL
oxygen	NULL
from	NULL
the	NULL
lower	NULL
hydrophobic	NULL
side	NULL
chain	NULL
was	NULL
removed	NULL
,	NULL
gave	NULL
similar	NULL
results	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
C-235	NULL
does	NULL
not	NULL
interact	NULL
with	NULL
the	NULL
side	NULL
chain	NULL
oxygen	NULL
.	NULL

Arginine	NULL
point	NULL
mutations	NULL
in	NULL
the	NULL
E	NULL
domain	NULL
of	NULL
hRARae	NULL
.	NULL

Since	NULL
the	NULL
free	NULL
carboxyl	NULL
group	NULL
on	NULL
retinoids	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
ligand	NULL
binding	NULL
to	NULL
RARs	NULL
(	NULL
3	NULL
,	NULL
21	NULL
)	NULL
,	NULL
a	NULL
positively	NULL
charged	NULL
arginine	NULL
or	NULL
lysine	NULL
residue	NULL
interaction	NULL
is	NULL
very	NULL
likely	NULL
.	NULL

We	NULL
first	NULL
used	NULL
2,3-butanedione	NULL
as	NULL
a	NULL
specific	NULL
arginine-blocking	NULL
reagent	NULL
and	NULL
found	NULL
a	NULL
decrease	NULL
of	NULL
binding	NULL
of	NULL
t-	NULL
RA	NULL
for	NULL
wt	NULL
hRARa-LBD	NULL
in	NULL
response	NULL
to	NULL
increasing	NULL
amounts	NULL
of	NULL
the	NULL
blocking	NULL
reagent	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Subsequently	NULL
,	NULL
a	NULL
triple	NULL
mutation	NULL
(	NULL
R364G	NULL
,	NULL
R366G	NULL
,	NULL
and	NULL
R367G	NULL
)	NULL
of	NULL
arginines	NULL
to	NULL
glycines	NULL
in	NULL
the	NULL
hRARa-LBD	NULL
was	NULL
made	NULL
.	NULL

This	NULL
mutated	NULL
receptor	NULL
exhibited	NULL
no	NULL
difference	NULL
in	NULL
binding	NULL
compared	NULL
with	NULL
the	NULL
wt	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

All	NULL
other	NULL
arginines	NULL
except	NULL
R-347	NULL
and	NULL
R-370	NULL
,	NULL
which	NULL
are	NULL
the	NULL
only	NULL
arginine	NULL
residues	NULL
that	NULL
are	NULL
not	NULL
conserved	NULL
among	NULL
the	NULL
subtypes	NULL
«	NULL
,	NULL
B	NULL
,	NULL
and	NULL
y	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
were	NULL
also	NULL
mutated	NULL
to	NULL
glycine	NULL
.	NULL

By	NULL
Scatchard	NULL
analysis	NULL
of	NULL
mutations	NULL
with	NULL
t-RA	NULL
and	NULL
9-cis-RA	NULL
ligands	NULL
,	NULL
we	NULL
identified	NULL
R217G	NULL
,	NULL
R272G	NULL
,	NULL
R276G	NULL
,	NULL
R294G	NULL
,	NULL
R339G	NULL
,	NULL
and	NULL
R394G	NULL
,	NULL
which	NULL
showed	NULL
a	NULL
50-	NULL
to	NULL
100-fold	NULL
reduction	NULL
in	NULL
binding	NULL
compared	NULL
with	NULL
the	NULL
wt	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
whereas	NULL
R385G	NULL
did	NULL
not	NULL
affect	NULL
binding	NULL
activity	NULL
at	NULL
all	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
R394G	NULL
mutant	NULL
was	NULL
very	NULL
low	NULL
,	NULL
and	NULL
we	NULL
were	NULL
able	NULL
to	NULL
define	NULL
an	NULL
ICs	NULL
,	NULL
value	NULL
only	NULL
as	NULL
higher	NULL
than	NULL
3,000	NULL
nM	NULL
for	NULL
both	NULL
t-RA	NULL
and	NULL
9-cis-RA	NULL
.	NULL

Figure	NULL
2B	NULL
shows	NULL
an	NULL
example	NULL
of	NULL
K	NULL
,	NULL
,	NULL
determination	NULL
(	NULL
for	NULL
R294G	NULL
)	NULL
.	NULL

TABLE	NULL
2	NULL
.	NULL

Effect	NULL
of	NULL
mutation	NULL
of	NULL
residues	NULL
R-217	NULL
,	NULL
R-276	NULL
,	NULL
R-294	NULL
,	NULL
R-394	NULL
,	NULL
and	NULL
C-235	NULL
on	NULL
binding	NULL
of	NULL
t-RA	NULL
and	NULL
the	NULL
antagonists	NULL
Ro	NULL
41-5253	NULL
,	NULL
Ro	NULL
46-5471	NULL
,	NULL
and	NULL
Ro	NULL
46-6464	NULL
1C	NULL
;	NULL
,	NULL
of	NULL
hRAR	NULL
&	NULL
-LBD	NULL
mutants	NULL
Structure	NULL
wt	NULL
©C235G	NULL
-	NULL
R2LIZA	NULL
_	NULL
R276A	NULL
R294A	NULL
R304A	NULL
t-RA	NULL
W	NULL
Ceo	NULL
``	NULL
4	NULL
5	NULL
5	NULL
1200	NULL
6	NULL
2500	NULL
Cod	NULL
Ro	NULL
41-5253	NULL
fig	NULL
n	NULL
,	NULL
O	NULL
48	NULL
-	NULL
3100	NULL
0	NULL
13	NULL
410	NULL
4	NULL
9200	NULL
|	NULL
3	NULL
in	NULL
ut	NULL
au	NULL
rt	NULL
``	NULL
|	NULL
e	NULL
Ro	NULL
46-5471	NULL
W	NULL
56	NULL
E50	NULL
14	NULL
6800	NULL
16	NULL
£900	NULL
5	NULL
NW	NULL
#	NULL
5	NULL
,	NULL
tool	NULL
Ro	NULL
46-6464	NULL
140	NULL
_	NULL
1500	NULL
_	NULL
17	NULL
2300	NULL
11	NULL
6200	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
A	NULL
A	NULL
-	NULL
total	NULL
binding	NULL
m	NULL
specific	NULL
binding	NULL
A	NULL
-	NULL
nonspecific	NULL
binding	NULL
n	NULL
2007	NULL
m	NULL
§	NULL
ise	NULL
120	NULL
=	NULL
m	NULL
h-5	NULL
&	NULL
so	NULL
for	NULL
&	NULL
190	NULL
401	NULL
Kd	NULL
s	NULL
1.4	NULL
nH	NULL
a	NULL
0	NULL
100	NULL
200	NULL
30g	NULL
50	NULL
B	NULL
{	NULL
fmol	NULL
}	NULL
I	NULL
’	NULL
M	NULL
0	NULL
t	NULL
t	NULL
t	NULL
t	NULL
r	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
b	NULL
E	NULL
[	NULL
3H	NULL
]	NULL
19-cis	NULL
RA	NULL
concentration	NULL
(	NULL
nM	NULL
}	NULL
SITE-DIRECTED	NULL
MUTAGENESIS	NULL
OF	NULL
hRARa	NULL
5389	NULL
B	NULL
600	NULL
O	NULL
toial	NULL
binding	NULL
w.	NULL
specific	NULL
binding	NULL
5007	NULL
A	NULL
|	NULL
nonspecific	NULL
binding	NULL
4004	NULL
4	NULL
0	NULL
E	NULL
a	NULL
Kd	NULL
=	NULL
114.	NULL
nM	NULL
g	NULL
2001	NULL
40	NULL
8	NULL
i	NULL
A	NULL
©	NULL
29	NULL
2004	NULL
200	NULL
400	NULL
1001	NULL
a	NULL
_	NULL
B	NULL
(	NULL
fmol	NULL
)	NULL
&	NULL
C	NULL
t	NULL
t	NULL
t	NULL
t	NULL
t	NULL
0	NULL
5	NULL
10	NULL
15	NULL
20	NULL
25	NULL
30	NULL
BH	NULL
]	NULL
IY-is	NULL
RA	NULL
concentration	NULL
(	NULL
nM	NULL
)	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Saturation-binding	NULL
analysis	NULL
of	NULL
9-cis-	NULL
[	NULL
°HJRA	NULL
binding	NULL
to	NULL
the	NULL
triple	NULL
mutant	NULL
hRAR	NULL
«	NULL
-LBD-R364G/R366G/R367G	NULL
(	NULL
A	NULL
)	NULL
and	NULL
to	NULL
the	NULL
single	NULL
mutant	NULL
hRARa-LBD-R294G	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Several	NULL
dilutions	NULL
of	NULL
protein	NULL
extract	NULL
containing	NULL
the	NULL
hRARa-LBD	NULL
from	NULL
E.	NULL
coli	NULL
BL21	NULL
were	NULL
used	NULL
to	NULL
test	NULL
the	NULL
binding	NULL
activity	NULL
to	NULL
define	NULL
the	NULL
appropriate	NULL
concentration	NULL
for	NULL
K	NULL
,	NULL
,	NULL
determination	NULL
.	NULL

The	NULL
nonspecific	NULL
binding	NULL
was	NULL
determined	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
RA	NULL
.	NULL

For	NULL
one	NULL
analysis	NULL
,	NULL
cach	NULL
point	NULL
represents	NULL
the	NULL
average	NULL
of	NULL
three	NULL
single	NULL
values	NULL
.	NULL

R276	NULL
and	NULL
R394	NULL
are	NULL
crucial	NULL
for	NULL
retinoid	NULL
binding	NULL
and	NULL
trans-activation	NULL
.	NULL

Since	NULL
glycine	NULL
is	NULL
the	NULL
smallest	NULL
amino	NULL
acid	NULL
(	NULL
no	NULL
side	NULL
chain	NULL
)	NULL
,	NULL
we	NULL
mutated	NULL
all	NULL
the	NULL
residues	NULL
mentioned	NULL
above	NULL
,	NULL
which	NULL
showed	NULL
a	NULL
reduction	NULL
in	NULL
binding	NULL
affinity	NULL
when	NULL
changed	NULL
to	NULL
polar	NULL
glycine	NULL
,	NULL
to	NULL
the	NULL
nonpolar	NULL
alanine	NULL
.	NULL

For	NULL
the	NULL
mutants	NULL
(	NULL
R217A	NULL
,	NULL
R294A	NULL
,	NULL
and	NULL
R339A	NULL
)	NULL
,	NULL
no	NULL
influence	NULL
was	NULL
detectable	NULL
compared	NULL
with	NULL
the	NULL
wt	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
what	NULL
was	NULL
seen	NULL
for	NULL
the	NULL
glycine	NULL
changes	NULL
above	NULL
.	NULL

The	NULL
binding	NULL
and	NULL
transactivation	NULL
activities	NULL
for	NULL
t-RA	NULL
and	NULL
Ro	NULL
13-7410	NULL
on	NULL
the	NULL
other	NULL
mutants	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
3	NULL
.	NULL

Only	NULL
a	NULL
10-fold	NULL
reduction	NULL
in	NULL
binding	NULL
efficiency	NULL
was	NULL
observed	NULL
for	NULL
mutant	NULL
R272A	NULL
,	NULL
whereas	NULL
300-	NULL
and	NULL
600-fold	NULL
reductions	NULL
were	NULL
seen	NULL
for	NULL
R276A	NULL
and	NULL
R394A	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
R394	NULL
mutant	NULL
has	NULL
in	NULL
addition	NULL
been	NULL
mutated	NULL
to	NULL
serine	NULL
or	NULL
glutamic	NULL
acid	NULL
,	NULL
and	NULL
more	NULL
or	NULL
less	NULL
the	NULL
same	NULL
600-fold	NULL
decrease	NULL
was	NULL
observed	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

Using	NULL
CV-1	NULL
cells	NULL
for	NULL
cotransfection	NULL
of	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
hRARa	NULL
cDNA	NULL
mutated	NULL
at	NULL
the	NULL
appropriate	NULL
residues	NULL
,	NULL
together	NULL
with	NULL
a	NULL
reporter	NULL
plasmid	NULL
containing	NULL
a	NULL
luciferase	NULL
gene	NULL
under	NULL
the	NULL
influence	NULL
of	NULL
the	NULL
BRARE	NULL
promoter	NULL
,	NULL
we	NULL
were	NULL
able	NULL
to	NULL
determine	NULL
the	NULL
transactivation	NULL
activity	NULL
for	NULL
hRARa	NULL
.	NULL

The	NULL
calculated	NULL
ECs	NULL
,	NULL
s	NULL
are	NULL
in	NULL
good	NULL
agreement	NULL
with	NULL
the	NULL
above-mentioned	NULL
binding	NULL
results	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

We	NULL
have	NULL
tested	NULL
all	NULL
mutants	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
bind	NULL
the	NULL
antagonist	NULL
Ro	NULL
41-5253	NULL
(	NULL
2	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
to	NULL
other	NULL
antagonists	NULL
.	NULL

For	NULL
most	NULL
mutations	NULL
,	NULL
we	NULL
found	NULL
no	NULL
effect	NULL
or	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
binding	NULL
affinity	NULL
to	NULL
the	NULL
same	NULL
degree	NULL
as	NULL
for	NULL
agonists	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
found	NULL
the	NULL
strongest	NULL
effect	NULL
for	NULL
mutations	NULL
R276A	NULL
and	NULL
R394A	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

The	NULL
mutation	NULL
R272A	NULL
on	NULL
hRARa	NULL
exhibited	NULL
only	NULL
a	NULL
slight	NULL
effect	NULL
.	NULL

For	NULL
the	NULL
antagonist	NULL
Ro	NULL
41-5253	NULL
,	NULL
we	NULL
observed	NULL
an	NULL
IC	NULL
,	NULL
,	NULL
of	NULL
210	NULL
nM	NULL
for	NULL
the	NULL
mutant	NULL
R272A	NULL
in	NULL
contrast	NULL
to	NULL
48	NULL
nM	NULL
for	NULL
wt	NULL
hRARa	NULL
.	NULL

Mutations	NULL
R217A	NULL
and	NULL
R294A	NULL
in	NULL
hRARa	NULL
«	NULL
-LBD	NULL
specifically	NULL
increase	NULL
the	NULL
binding	NULL
efficiency	NULL
of	NULL
antagonists	NULL
.	NULL

While	NULL
testing	NULL
all	NULL
arginine	NULL
mutants	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
bind	NULL
antagonists	NULL
we	NULL
observed	NULL
two	NULL
mutants	NULL
,	NULL
hRAR	NULL
«	NULL
-R217A	NULL
and	NULL
hRARoe-R294A	NULL
,	NULL
which	NULL
showed	NULL
a	NULL
higher	NULL
binding	NULL
affinity	NULL
for	NULL
the	NULL
antagonists	NULL
Ro	NULL
41-5253	NULL
,	NULL
Ro	NULL
46-5471	NULL
,	NULL
and	NULL
Ro	NULL
46-6464	NULL
,	NULL
than	NULL
did	NULL
the	NULL
wt	NULL
receptor	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

The	NULL
same	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
several	NULL
other	NULL
antagonists	NULL
which	NULL
we	NULL
have	NULL
also	NULL
tested	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

For	NULL
all	NULL
antagonists	NULL
,	NULL
the	NULL
increase	NULL
in	NULL
affinity	NULL
was	NULL
between	NULL
2-	NULL
and	NULL
12-fold	NULL
for	NULL
both	NULL
mutants	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
wt	NULL
.	NULL

The	NULL
limited	NULL
proteolytic	NULL
digestion	NULL
pattern	NULL
of	NULL
the	NULL
R217A	NULL
mutant	NULL
for	NULL
antagonists	NULL
is	NULL
different	NULL
from	NULL
that	NULL
of	NULL
the	NULL
wt	NULL
,	NULL
but	NULL
antagonist	NULL
function	NULL
is	NULL
retained	NULL
.	NULL

To	NULL
verify	NULL
the	NULL
influence	NULL
of	NULL
the	NULL
mutations	NULL
on	NULL
ligand	NULL
function	NULL
,	NULL
we	NULL
first	NULL
checked	NULL
the	NULL
protection	NULL
specificity	NULL
by	NULL
protease	NULL
mapping	NULL
with	NULL
trypsin	NULL
,	NULL
chymotrypsin	NULL
,	NULL
and	NULL
elastase	NULL
.	NULL

We	NULL
did	NULL
not	NULL
notice	NULL
any	NULL
difference	NULL
for	NULL
hRAR	NULL
«	NULL
-C235G	NULL
and	NULL
hRAR	NULL
«	NULL
-R294A	NULL
compared	NULL
with	NULL
the	NULL
wt	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Only	NULL
for	NULL
trypsin	NULL
digestion	NULL
of	NULL
hRARa	NULL
«	NULL
-R217A	NULL
did	NULL
we	NULL
find	NULL
a	NULL
different	NULL
pattern	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
antagonist	NULL
Ro	NULL
41-5253	NULL
TABLE	NULL
3	NULL
.	NULL

Effect	NULL
of	NULL
mutation	NULL
of	NULL
residues	NULL
R-272	NULL
,	NULL
R-276	NULL
,	NULL
and	NULL
R-394	NULL
on	NULL
binding	NULL
and	NULL
transactivation	NULL
activity	NULL
for	NULL
t-RA	NULL
and	NULL
the	NULL
agonist	NULL
Ro	NULL
13-7410	NULL
Transactivation	NULL
Binding	NULL
Activity	NULL
Activity	NULL
Chemical	NULL
structure	NULL
hRARa	NULL
EC	NULL
;	NULL
,	NULL
{	NULL
aM	NULL
)	NULL
a	NULL
C3	NULL
,	NULL
(	NULL
aM	NULL
)	NULL
P	NULL
t-RA	NULL
wh	NULL
5.5	NULL
4	NULL
RZ7z2A	NULL
50	NULL
45	NULL
R276A	NULL
160	NULL
1200	NULL
a	NULL
a	NULL
tr	NULL
y	NULL
*C	NULL
5	NULL
118	NULL
2500	NULL
R3945	NULL
140	NULL
2300	NULL
R394E	NULL
195	NULL
3400	NULL
Ro	NULL
13-7410	NULL
wih	NULL
1.2	NULL
4	NULL
©€0OH	NULL
R272A	NULL
29	NULL
26	NULL
RZ76A	NULL
130	NULL
600	NULL
m.	NULL
O	NULL
R3Y4A	NULL
33	NULL
1500	NULL
R394S	NULL
65	NULL
2100	NULL
‘	NULL
O	NULL
R3Y4E	NULL
175	NULL
2300	NULL
``	NULL
For	NULL
transactivation	NULL
,	NULL
CV-1	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
one	NULL
of	NULL
the	NULL
hRARa	NULL
expression	NULL
vectors	NULL
(	NULL
wt	NULL
or	NULL
mutant	NULL
)	NULL
and	NULL
the	NULL
BRARE-luciferase	NULL
reporter	NULL
.	NULL

After	NULL
addition	NULL
of	NULL
t-RA	NULL
or	NULL
Ro	NULL
13-7410	NULL
and	NULL
incubation	NULL
for	NULL
36	NULL
h	NULL
,	NULL
the	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
and	NULL
the	NULL
ECs	NULL
,	NULL
was	NULL
calculated	NULL
.	NULL

ECs	NULL
,	NULL
is	NULL
defined	NULL
as	NULL
the	NULL
retinoid	NULL
concentration	NULL
required	NULL
to	NULL
obtain	NULL
50	NULL
%	NULL
of	NULL
the	NULL
maximal	NULL
response	NULL
(	NULL
at	NULL
1,000	NULL
nM	NULL
)	NULL
.	NULL

``	NULL
ICs	NULL
,	NULL
is	NULL
the	NULL
retinoid	NULL
concentration	NULL
required	NULL
to	NULL
inhibit	NULL
50	NULL
%	NULL
of	NULL
specific	NULL
RA	NULL
binding	NULL
.	NULL

5390	NULL
LAMOUR	NULL
ET	NULL
AL	NULL
.	NULL

hRARa	NULL
:	NULL
hRARa-R217A	NULL
t-RA	NULL
=o	NULL
-	NULL
=	NULL
#	NULL
#	NULL
-	NULL
-	NULL
o=	NULL
waw	NULL
ue	NULL
ogo	NULL
ye	NULL
(	NULL
e	NULL
Wi	NULL
oon	NULL
Ro	NULL
41-5253	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
+	NULL
+	NULL
+	NULL
Lan	NULL
ance	NULL
yoo	NULL
w	NULL
Trypsin	NULL
pg/ml	NULL
0	NULL
10	NULL
100	NULL
10	NULL
100	NULL
10	NULL
50	NULL
100	NULL
0	NULL
10	NULL
100	NULL
10	NULL
100	NULL
10	NULL
50100	NULL
300	NULL
lane	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
M	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
M_	NULL
kDa	NULL
me	NULL
mame|	NULL
220	NULL
4	NULL
w	NULL
|	NULL
97	NULL
l	NULL
..	NULL
wa	NULL
|	NULL
6s	NULL
#	NULL
p	NULL
w	NULL
|	NULL
46	NULL
-..	NULL
``	NULL
'-30	NULL
&	NULL
san	NULL
.	NULL

dill	NULL
>	NULL
#	NULL
¥	NULL
%	NULL
©	NULL
6d	NULL
~	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Effect	NULL
of	NULL
t-RA	NULL
and	NULL
the	NULL
antagonist	NULL
Ro	NULL
41-5253	NULL
on	NULL
limited	NULL
trypsin	NULL
digestion	NULL
of	NULL
wt	NULL
and	NULL
hRARa-R217A	NULL
.	NULL

The	NULL
in	NULL
vitro-translated	NULL
hRARa	NULL
«	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
8	NULL
)	NULL
and	NULL
hRARa-R217A	NULL
(	NULL
lanes	NULL
9	NULL
to	NULL
17	NULL
)	NULL
were	NULL
preincubated	NULL
with	NULL
DMSO	NULL
alone	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
10	NULL
,	NULL
and	NULL
11	NULL
)	NULL
or	NULL
with	NULL
1	NULL
M	NULL
t-RA	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
5	NULL
,	NULL
12	NULL
,	NULL
and	NULL
13	NULL
)	NULL
or	NULL
1	NULL
wM	NULL
Ro	NULL
41-5253	NULL
(	NULL
lanes	NULL
6	NULL
to	NULL
8	NULL
and	NULL
14	NULL
to	NULL
17	NULL
)	NULL
and	NULL
then	NULL
digested	NULL
with	NULL
the	NULL
indicated	NULL
concentration	NULL
of	NULL
trypsin	NULL
.	NULL

The	NULL
mixtures	NULL
were	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
tempera-ture	NULL
.	NULL

Samples	NULL
were	NULL
electrophoresed	NULL
through	NULL
an	NULL
SDS-12	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
,	NULL
and	NULL
the	NULL
dried	NULL
gel	NULL
was	NULL
autoradiographed	NULL
.	NULL

The	NULL
sizes	NULL
of	NULL
molecular	NULL
mass	NULL
markers	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
resistant	NULL
protein	NULL
fragment	NULL
occurring	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
t-RA	NULL
is	NULL
marked	NULL
by	NULL
a	NULL
open	NULL
diamond	NULL
,	NULL
the	NULL
resistant	NULL
fragment	NULL
characteristic	NULL
of	NULL
the	NULL
antagonist	NULL
is	NULL
indicated	NULL
by	NULL
a	NULL
solid	NULL
diamond	NULL
,	NULL
and	NULL
the	NULL
newly	NULL
occurring	NULL
fragment	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
asterisk	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Protease	NULL
mapping	NULL
of	NULL
the	NULL
wt	NULL
hRARa	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
ligand	NULL
results	NULL
in	NULL
a	NULL
complete	NULL
digestion	NULL
of	NULL
the	NULL
receptor	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
,	NULL
whereas	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
t-RA	NULL
we	NULL
saw	NULL
a	NULL
30-kDa	NULL
band	NULL
protected	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
antagonist	NULL
Ro	NULL
A	NULL
Luciferase	NULL
activity	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
10000	NULL
Ro	NULL
41-5253	NULL
concentration	NULL
{	NULL
nM	NULL
}	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

41-5253	NULL
a	NULL
25-kDa	NULL
band	NULL
was	NULL
protected	NULL
(	NULL
lanes	NULL
6	NULL
to	NULL
8	NULL
)	NULL
as	NULL
previously	NULL
shown	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
this	NULL
specific	NULL
antagonist-induced	NULL
protection	NULL
changed	NULL
with	NULL
the	NULL
hRARa-R217A	NULL
mutant	NULL
.	NULL

At	NULL
low	NULL
trypsin	NULL
concentrations	NULL
(	NULL
lane	NULL
14	NULL
)	NULL
,	NULL
we	NULL
were	NULL
able	NULL
to	NULL
see	NULL
mainly	NULL
a	NULL
30-kDa	NULL
band	NULL
corresponding	NULL
to	NULL
the	NULL
agonist	NULL
band	NULL
and	NULL
a	NULL
very	NULL
weak	NULL
lower	NULL
band	NULL
.	NULL

At	NULL
higher	NULL
trypsin	NULL
concentrations	NULL
(	NULL
lanes	NULL
15	NULL
to	NULL
17	NULL
)	NULL
,	NULL
we	NULL
saw	NULL
a	NULL
dose-dependent	NULL
conversion	NULL
of	NULL
the	NULL
30-kDa	NULL
agonist	NULL
band	NULL
to	NULL
the	NULL
lower	NULL
26-kDa	NULL
band	NULL
,	NULL
which	NULL
is	NULL
around	NULL
1	NULL
kDa	NULL
larger	NULL
than	NULL
the	NULL
protected	NULL
band	NULL
in	NULL
the	NULL
experiments	NULL
with	NULL
the	NULL
wt	NULL
receptor	NULL
.	NULL

Using	NULL
the	NULL
antagonist	NULL
Ro	NULL
46-5471	NULL
,	NULL
we	NULL
found	NULL
the	NULL
same	NULL
result	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
answer	NULL
the	NULL
question	NULL
whether	NULL
the	NULL
mutation	NULL
hRARa	NULL
«	NULL
-R217A	NULL
changed	NULL
the	NULL
function	NULL
of	NULL
an	NULL
antagonist	NULL
into	NULL
that	NULL
of	NULL
an	NULL
agonist	NULL
,	NULL
we	NULL
have	NULL
performed	NULL
transactivation	NULL
experiments	NULL
to	NULL
verify	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
two	NULL
antagonists	NULL
to	NULL
antagonize	NULL
the	NULL
t-RA	NULL
induced	NULL
transactivation	NULL
of	NULL
a	NULL
reporter	NULL
system	NULL
.	NULL

The	NULL
results	NULL
for	NULL
Ro	NULL
41-5253	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
(	NULL
with	NULL
wt	NULL
and	NULL
hRARa-R217A	NULL
)	NULL
.	NULL

When	NULL
the	NULL
antagonist	NULL
was	NULL
used	NULL
alone	NULL
,	NULL
for	NULL
both	NULL
wt	NULL
and	NULL
mutant	NULL
receptors	NULL
there	NULL
was	NULL
no	NULL
induction	NULL
of	NULL
the	NULL
luciferase	NULL
;	NULL
at	NULL
three	NULL
different	NULL
concentrations	NULL
of	NULL
t-RA	NULL
(	NULL
1	NULL
,	NULL
10	NULL
,	NULL
and	NULL
100	NULL
nM	NULL
)	NULL
,	NULL
and	NULL
increasing	NULL
amounts	NULL
of	NULL
Ro	NULL
41-5253	NULL
,	NULL
the	NULL
antagonist	NULL
was	NULL
able	NULL
to	NULL
antagonize	NULL
the	NULL
t-RA	NULL
effect	NULL
with	NULL
either	NULL
wt	NULL
or	NULL
mutant	NULL
receptor	NULL
.	NULL

DISCUSSION	NULL
The	NULL
results	NULL
of	NULL
the	NULL
present	NULL
work	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
crystal	NULL
structure	NULL
of	NULL
the	NULL
holo-hRARy-LBD	NULL
defined	NULL
by	NULL
Renaud	NULL
et	NULL
al	NULL
.	NULL

(	NULL
39	NULL
)	NULL
and	NULL
provide	NULL
new	NULL
information	NULL
about	NULL
this	NULL
receptor	NULL
family	NULL
.	NULL

A	NULL
high	NULL
homology	NULL
has	NULL
been	NULL
observed	NULL
between	NULL
the	NULL
holo-hRARy-LBD	NULL
structure	NULL
and	NULL
the	NULL
recently	NULL
reported	NULL
structure	NULL
of	NULL
apo-hRXRa-LBD	NULL
(	NULL
8	NULL
)	NULL
.	NULL

In	NULL
this	NULL
latter	NULL
receptor	NULL
,	NULL
two	NULL
arginine	NULL
residues	NULL
(	NULL
R-274	NULL
and	NULL
R-278	NULL
)	NULL
integrate	NULL
a	NULL
cluster	NULL
of	NULL
positively	NULL
charged	NULL
residues	NULL
which	NULL
play	NULL
a	NULL
role	NULL
in	NULL
electrostatic	NULL
guidance	NULL
.	NULL

R-278	NULL
interacts	NULL
specifically	NULL
with	NULL
the	NULL
carboxyl	NULL
group	NULL
of	NULL
t-	NULL
RA	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
changing	NULL
R-276	NULL
of	NULL
hRAR	NULL
«	NULL
-LBD	NULL
(	NULL
R-278	NULL
of	NULL
hRARy	NULL
)	NULL
into	NULL
either	NULL
a	NULL
small	NULL
polar	NULL
glycine	NULL
or	NULL
small	NULL
nonpolar	NULL
alanine	NULL
residue	NULL
results	NULL
in	NULL
a	NULL
decreased	NULL
binding	NULL
affinity	NULL
to	NULL
the	NULL
mutant	NULL
receptor	NULL
for	NULL
all	NULL
ligands	NULL
tested	NULL
.	NULL

For	NULL
all	NULL
ligands	NULL
tested	NULL
,	NULL
we	NULL
have	NULL
also	NULL
seen	NULL
a	NULL
small	NULL
reduction	NULL
in	NULL
binding	NULL
affinity	NULL
for	NULL
the	NULL
hRARa	NULL
mutants	NULL
at	NULL
position	NULL
R-272	NULL
200	NULL
100nM	NULL
R217A	NULL
150	NULL
10nM	NULL
Luciferase	NULL
activity	NULL
a	NULL
G	NULL
£0	NULL
OnM	NULL
+/	NULL
r	NULL
t	NULL
t	NULL
1	NULL
--	NULL
i	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
10000	NULL
Ro	NULL
41-5253	NULL
concentration	NULL
(	NULL
nM	NULL
)	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Influence	NULL
of	NULL
the	NULL
antagonist	NULL
Ro	NULL
41-5253	NULL
on	NULL
transactivation	NULL
induced	NULL
by	NULL
t-RA	NULL
in	NULL
CV-1	NULL
cells	NULL
transfected	NULL
with	NULL
hRARa	NULL
(	NULL
A	NULL
)	NULL
or	NULL
hRARa-R217A	NULL
(	NULL
B	NULL
)	NULL
and	NULL
the	NULL
BRARE-luciferase	NULL
reporter	NULL
plasmid	NULL
.	NULL

At	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
0	NULL
,	NULL
1	NULL
,	NULL
10	NULL
,	NULL
and	NULL
100	NULL
nM	NULL
t-RA	NULL
and	NULL
increasing	NULL
amounts	NULL
of	NULL
the	NULL
antagonist	NULL
Ro	NULL
41-5253	NULL
were	NULL
added	NULL
to	NULL
the	NULL
cultures	NULL
;	NULL
after	NULL
a	NULL
36-h	NULL
incubation	NULL
,	NULL
the	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
(	NULL
R-274	NULL
of	NULL
hRARy	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
transactivation	NULL
experiments	NULL
with	NULL
t-RA	NULL
or	NULL
Ro	NULL
13-7410	NULL
showed	NULL
an	NULL
increase	NULL
in	NULL
ECs	NULL
,	NULL
values	NULL
for	NULL
both	NULL
ligands	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
binding	NULL
activity	NULL
.	NULL

This	NULL
effect	NULL
of	NULL
residue	NULL
R-272	NULL
on	NULL
binding	NULL
and	NULL
transactivation	NULL
provides	NULL
functional	NULL
evidence	NULL
of	NULL
its	NULL
involvement	NULL
in	NULL
ligand	NULL
binding	NULL
.	NULL

We	NULL
have	NULL
clearly	NULL
demonstrated	NULL
that	NULL
R-394	NULL
of	NULL
hRARa	NULL
(	NULL
R-396	NULL
of	NULL
hRARy	NULL
)	NULL
is	NULL
a	NULL
crucial	NULL
residue	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
all	NULL
ligands	NULL
tested	NULL
.	NULL

A	NULL
mutation	NULL
of	NULL
the	NULL
next	NULL
residue	NULL
,	NULL
A-397	NULL
of	NULL
hRARy	NULL
,	NULL
to	NULL
threonine	NULL
caused	NULL
only	NULL
a	NULL
slight	NULL
effect	NULL
on	NULL
binding	NULL
activity	NULL
(	NULL
39	NULL
)	NULL
.	NULL

This	NULL
decrease	NULL
of	NULL
binding	NULL
could	NULL
be	NULL
due	NULL
to	NULL
the	NULL
perturbation	NULL
of	NULL
the	NULL
R-396	NULL
spatial	NULL
position	NULL
.	NULL

It	NULL
appears	NULL
that	NULL
not	NULL
all	NULL
the	NULL
residues	NULL
involved	NULL
in	NULL
the	NULL
binding	NULL
pocket	NULL
have	NULL
the	NULL
same	NULL
importance	NULL
for	NULL
ligand	NULL
binding	NULL
.	NULL

R-394	NULL
of	NULL
hRARa	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
part	NULL
of	NULL
the	NULL
ligand-binding	NULL
site	NULL
close	NULL
to	NULL
the	NULL
ring	NULL
of	NULL
t-RA	NULL
.	NULL

Since	NULL
changing	NULL
R-394	NULL
into	NULL
residues	NULL
with	NULL
different	NULL
characteristics	NULL
(	NULL
G	NULL
,	NULL
S	NULL
,	NULL
A	NULL
,	NULL
and	NULL
E	NULL
)	NULL
yielded	NULL
the	NULL
same	NULL
dramatic	NULL
effect	NULL
and	NULL
considering	NULL
the	NULL
spatial	NULL
location	NULL
of	NULL
this	NULL
position	NULL
in	NULL
the	NULL
ligand-binding	NULL
pocket	NULL
,	NULL
there	NULL
are	NULL
two	NULL
possible	NULL
explanations	NULL
for	NULL
the	NULL
results	NULL
.	NULL

It	NULL
could	NULL
be	NULL
that	NULL
this	NULL
change	NULL
in	NULL
«	NULL
-helix	NULL
11	NULL
disturbs	NULL
its	NULL
structural	NULL
function	NULL
in	NULL
such	NULL
a	NULL
way	NULL
that	NULL
«	NULL
-helix	NULL
12	NULL
can	NULL
no	NULL
longer	NULL
play	NULL
the	NULL
``	NULL
lid	NULL
role	NULL
``	NULL
to	NULL
close	NULL
off	NULL
the	NULL
binding	NULL
cavity	NULL
.	NULL

Arguing	NULL
against	NULL
this	NULL
hypothesis	NULL
are	NULL
the	NULL
facts	NULL
that	NULL
it	NULL
is	NULL
still	NULL
possible	NULL
to	NULL
transactivate	NULL
the	NULL
mutated	NULL
receptors	NULL
and	NULL
that	NULL
the	NULL
normal	NULL
agonist	NULL
band	NULL
is	NULL
still	NULL
protected	NULL
in	NULL
protease-mapping	NULL
studies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
more	NULL
credible	NULL
explanation	NULL
could	NULL
be	NULL
that	NULL
the	NULL
R394	NULL
interacts	NULL
via	NULL
its	NULL
hydrophobic	NULL
portion	NULL
with	NULL
the	NULL
t-RA	NULL
ring	NULL
and	NULL
in	NULL
this	NULL
way	NULL
it	NULL
contributes	NULL
to	NULL
the	NULL
high-affinity	NULL
binding	NULL
of	NULL
the	NULL
retinoid	NULL
.	NULL

From	NULL
our	NULL
binding	NULL
results	NULL
of	NULL
the	NULL
hRARa	NULL
«	NULL
cysteine	NULL
point	NULL
mu-tant	NULL
,	NULL
no	NULL
change	NULL
in	NULL
binding	NULL
efficiency	NULL
for	NULL
single	NULL
mutants	NULL
was	NULL
noticeable	NULL
except	NULL
for	NULL
the	NULL
mutation	NULL
€265G	NULL
.	NULL

For	NULL
this	NULL
residue	NULL
,	NULL
although	NULL
the	NULL
single	NULL
alanine	NULL
mutation	NULL
did	NULL
not	NULL
significantly	NULL
change	NULL
the	NULL
affinity	NULL
of	NULL
hRARa	NULL
«	NULL
-LBD	NULL
for	NULL
ligands	NULL
,	NULL
we	NULL
did	NULL
observe	NULL
a	NULL
strong	NULL
effect	NULL
for	NULL
the	NULL
double	NULL
mutant	NULL
C265G/C274G	NULL
.	NULL

Interestingly	NULL
,	NULL
these	NULL
two	NULL
cysteines	NULL
are	NULL
both	NULL
involved	NULL
in	NULL
«	NULL
-helix	NULL
5	NULL
,	NULL
which	NULL
in	NULL
hRARy	NULL
contains	NULL
hydrophobic	NULL
residues	NULL
interacting	NULL
with	NULL
the	NULL
ligand-binding	NULL
pocket	NULL
.	NULL

We	NULL
assume	NULL
that	NULL
the	NULL
modification	NULL
of	NULL
both	NULL
cysteines	NULL
disturbs	NULL
the	NULL
«	NULL
-helix	NULL
too	NULL
severely	NULL
whereas	NULL
each	NULL
single	NULL
mutation	NULL
has	NULL
a	NULL
less	NULL
dramatic	NULL
effect	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
specific	NULL
influence	NULL
of	NULL
C-235	NULL
of	NULL
hRARa	NULL
(	NULL
C-237	NULL
of	NULL
hRARy	NULL
)	NULL
on	NULL
antagonist	NULL
binding	NULL
has	NULL
been	NULL
established	NULL
.	NULL

For	NULL
agonists	NULL
,	NULL
the	NULL
binding	NULL
affinity	NULL
was	NULL
the	NULL
same	NULL
for	NULL
the	NULL
C235G	NULL
mutant	NULL
as	NULL
for	NULL
the	NULL
wt	NULL
,	NULL
whereas	NULL
with	NULL
antagonists	NULL
,	NULL
a	NULL
tremendous	NULL
decrease	NULL
in	NULL
binding	NULL
affinity	NULL
was	NULL
shown	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
a	NULL
putative	NULL
interaction	NULL
involving	NULL
the	NULL
hydrophobic	NULL
side	NULL
chain	NULL
,	NULL
common	NULL
to	NULL
all	NULL
the	NULL
antagonists	NULL
yet	NULL
absent	NULL
from	NULL
agonists	NULL
,	NULL
might	NULL
be	NULL
disrupted	NULL
by	NULL
this	NULL
mutation	NULL
in	NULL
«	NULL
-helix	NULL
3	NULL
.	NULL

Furthermore	NULL
,	NULL
since	NULL
«	NULL
-helix	NULL
3	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
transconformation	NULL
of	NULL
«	NULL
-helix	NULL
12	NULL
,	NULL
which	NULL
is	NULL
necessary	NULL
for	NULL
agonist	NULL
activity	NULL
,	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
antagonist	NULL
side	NULL
chain	NULL
with	NULL
«	NULL
-helix	NULL
3	NULL
may	NULL
be	NULL
part	NULL
of	NULL
the	NULL
antagonistic	NULL
mechanism	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
the	NULL
mutation	NULL
to	NULL
alanine	NULL
of	NULL
either	NULL
of	NULL
two	NULL
residues	NULL
,	NULL
R-217	NULL
and	NULL
R-294	NULL
of	NULL
hRARa	NULL
,	NULL
causes	NULL
a	NULL
specific	NULL
increase	NULL
of	NULL
antagonist-binding	NULL
efficiency	NULL
.	NULL

This	NULL
provides	NULL
evidence	NULL
for	NULL
the	NULL
distinctive	NULL
implication	NULL
of	NULL
these	NULL
two	NULL
residues	NULL
in	NULL
antagonist	NULL
binding	NULL
.	NULL

According	NULL
to	NULL
the	NULL
hRARy	NULL
structure	NULL
,	NULL
R-217	NULL
should	NULL
be	NULL
located	NULL
in	NULL
the	NULL
-loop	NULL
just	NULL
before	NULL
the	NULL
beginning	NULL
of	NULL
«	NULL
-helix	NULL
3	NULL
and	NULL
R-294	NULL
would	NULL
start	NULL
«	NULL
-helix	NULL
6	NULL
.	NULL

From	NULL
the	NULL
apo-hRXRa	NULL
«	NULL
and	NULL
holo-hRARy	NULL
crystal	NULL
structures	NULL
,	NULL
a	NULL
mousetrap	NULL
mechanism	NULL
has	NULL
been	NULL
postulated	NULL
to	NULL
sequester	NULL
the	NULL
ligand	NULL
and	NULL
transactivate	NULL
target	NULL
genes	NULL
via	NULL
conformational	NULL
changes	NULL
(	NULL
39	NULL
)	NULL
.	NULL

This	NULL
change	NULL
would	NULL
involved	NULL
the	NULL
-loop	NULL
flipping	NULL
over	NULL
«	NULL
-helix	NULL
6	NULL
,	NULL
which	NULL
would	NULL
also	NULL
shift	NULL
position	NULL
to	NULL
result	NULL
in	NULL
a	NULL
more	NULL
compact	NULL
structure	NULL
.	NULL

Using	NULL
trypsin	NULL
digestion	NULL
,	NULL
a	NULL
specific	NULL
protease-mapping	NULL
pattern	NULL
has	NULL
been	NULL
found	NULL
for	NULL
antagonists	NULL
,	NULL
giving	NULL
a	NULL
25-kDa	NULL
protected	NULL
fragment	NULL
for	NULL
hRARa	NULL
«	NULL
versus	NULL
a	NULL
30-kDa	NULL
protected	NULL
fragment	NULL
for	NULL
bound	NULL
agonists	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Strikingly	NULL
,	NULL
at	NULL
the	NULL
low	NULL
trypsin	NULL
SITE-DIRECTED	NULL
MUTAGENESIS	NULL
OF	NULL
hRARa	NULL
5391	NULL
concentrations	NULL
used	NULL
,	NULL
the	NULL
pattern	NULL
of	NULL
antagonist	NULL
bound	NULL
to	NULL
hRARa	NULL
«	NULL
-R217A	NULL
showed	NULL
two	NULL
bands	NULL
protected	NULL
,	NULL
consisting	NULL
of	NULL
a	NULL
main	NULL
30-kDa	NULL
agonist	NULL
band	NULL
and	NULL
a	NULL
new	NULL
band	NULL
about	NULL
1	NULL
kDa	NULL
heavier	NULL
than	NULL
the	NULL
antagonist-specific	NULL
band	NULL
observed	NULL
with	NULL
the	NULL
wt	NULL
receptor	NULL
.	NULL

It	NULL
has	NULL
been	NULL
previously	NULL
demonstrated	NULL
that	NULL
the	NULL
C-terminal	NULL
cleavage	NULL
site	NULL
of	NULL
the	NULL
antagonist	NULL
band	NULL
is	NULL
located	NULL
between	NULL
amino	NULL
acids	NULL
420	NULL
and	NULL
438	NULL
(	NULL
18	NULL
)	NULL
.	NULL

To	NULL
obtain	NULL
a	NULL
protected	NULL
fragment	NULL
of	NULL
25	NULL
kDa	NULL
,	NULL
the	NULL
N-terminal	NULL
cleavage	NULL
site	NULL
has	NULL
to	NULL
be	NULL
approximately	NULL
at	NULL
residue	NULL
210	NULL
.	NULL

The	NULL
residue	NULL
R-217	NULL
is	NULL
located	NULL
in	NULL
the	NULL
flexible	NULL
O-loop	NULL
,	NULL
which	NULL
should	NULL
be	NULL
an	NULL
accessible	NULL
site	NULL
for	NULL
trypsin	NULL
cleavage	NULL
.	NULL

All	NULL
other	NULL
sites	NULL
would	NULL
be	NULL
less	NULL
accessible	NULL
for	NULL
trypsin	NULL
,	NULL
according	NULL
to	NULL
the	NULL
three-dimensional	NULL
structure	NULL
of	NULL
hRARy	NULL
.	NULL

We	NULL
postulate	NULL
that	NULL
by	NULL
mutating	NULL
R-217	NULL
,	NULL
the	NULL
N-terminal	NULL
trypsin	NULL
cleavage	NULL
site	NULL
is	NULL
destroyed	NULL
.	NULL

In	NULL
the	NULL
protease	NULL
mapping	NULL
experiments	NULL
,	NULL
the	NULL
next	NULL
most	NULL
accessible	NULL
site	NULL
would	NULL
be	NULL
preferentially	NULL
cleaved	NULL
at	NULL
low	NULL
trypsin	NULL
concentration	NULL
,	NULL
which	NULL
would	NULL
correspond	NULL
in	NULL
our	NULL
case	NULL
to	NULL
the	NULL
agonist	NULL
band	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

At	NULL
higher	NULL
concentrations	NULL
,	NULL
the	NULL
less	NULL
accessible	NULL
site	NULL
,	NULL
located	NULL
10	NULL
residues	NULL
upstream	NULL
(	NULL
K-207	NULL
)	NULL
would	NULL
be	NULL
cleaved	NULL
,	NULL
yielding	NULL
the	NULL
1-kDa	NULL
larger	NULL
band	NULL
observed	NULL
.	NULL

Competition	NULL
experiments	NULL
for	NULL
transactivation	NULL
between	NULL
t-RA	NULL
and	NULL
antagonists	NULL
(	NULL
Ro	NULL
41-5253	NULL
or	NULL
Ro	NULL
46-5471	NULL
)	NULL
have	NULL
established	NULL
that	NULL
hRAR	NULL
«	NULL
-R217A	NULL
still	NULL
allows	NULL
these	NULL
compounds	NULL
to	NULL
retain	NULL
their	NULL
antagonist	NULL
activity	NULL
.	NULL

It	NULL
means	NULL
that	NULL
the	NULL
antagonists	NULL
are	NULL
most	NULL
probably	NULL
still	NULL
able	NULL
to	NULL
induce	NULL
the	NULL
specific	NULL
antagonist	NULL
conformational	NULL
change	NULL
.	NULL

Then	NULL
,	NULL
R-217	NULL
is	NULL
probably	NULL
the	NULL
N-terminal	NULL
cleavage	NULL
site	NULL
of	NULL
trypsin	NULL
in	NULL
wt	NULL
hRARa-bound-antagonist	NULL
protection	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
role	NULL
of	NULL
R-394	NULL
,	NULL
three	NULL
residues	NULL
,	NULL
C-235	NULL
(	NULL
re-lated	NULL
to	NULL
the	NULL
binding	NULL
pocket	NULL
)	NULL
,	NULL
R-217	NULL
,	NULL
and	NULL
R-294	NULL
(	NULL
both	NULL
of	NULL
which	NULL
are	NULL
not	NULL
related	NULL
to	NULL
the	NULL
binding	NULL
pocket	NULL
)	NULL
,	NULL
are	NULL
implicated	NULL
specifically	NULL
in	NULL
antagonist	NULL
binding	NULL
.	NULL

Interacting	NULL
in	NULL
stirring	NULL
regions	NULL
according	NULL
to	NULL
the	NULL
three-dimensional	NULL
structure	NULL
of	NULL
hRARy	NULL
,	NULL
the	NULL
antagonists	NULL
could	NULL
block	NULL
the	NULL
transitional	NULL
step	NULL
required	NULL
for	NULL
transactivation	NULL
activity	NULL
.	NULL

We	NULL
also	NULL
observed	NULL
a	NULL
60-fold	NULL
decrease	NULL
of	NULL
Ro	NULL
41-5253	NULL
antagonist-binding	NULL
activity	NULL
for	NULL
the	NULL
hRAR	NULL
«	NULL
-C235G	NULL
,	NULL
whereas	NULL
the	NULL
R276A	NULL
mutation	NULL
caused	NULL
only	NULL
an	NULL
8-fold	NULL
reduction	NULL
.	NULL

Noticeably	NULL
,	NULL
the	NULL
antagonist	NULL
Ro	NULL
46-5471	NULL
showed	NULL
an	NULL
11-fold	NULL
reduction	NULL
in	NULL
binding	NULL
for	NULL
the	NULL
C235G	NULL
mutation	NULL
while	NULL
R276A	NULL
caused	NULL
a	NULL
110-fold	NULL
decrease	NULL
of	NULL
binding	NULL
activity	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

There-fore	NULL
,	NULL
it	NULL
seems	NULL
that	NULL
the	NULL
roles	NULL
of	NULL
these	NULL
two	NULL
residues	NULL
are	NULL
counterbalanced	NULL
in	NULL
the	NULL
binding	NULL
pocket	NULL
depending	NULL
on	NULL
the	NULL
chemical	NULL
structure	NULL
of	NULL
the	NULL
antagonist	NULL
,	NULL
giving	NULL
a	NULL
certain	NULL
flexibility	NULL
to	NULL
the	NULL
binding	NULL
pocket	NULL
and	NULL
thus	NULL
allowing	NULL
the	NULL
binding	NULL
of	NULL
different	NULL
li-gands	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
M.	NULL
Klaus	NULL
,	NULL
F.	NULL
Hoffmann-La	NULL
Roche	NULL
Ltd.	NULL
,	NULL
Basel	NULL
,	NULL
Switzer-land	NULL
,	NULL
for	NULL
synthesizing	NULL
the	NULL
retinoids	NULL
and	NULL
P.	NULL
LeMotte	NULL
,	NULL
S.	NULL
Keidel	NULL
,	NULL
and	NULL
W.	NULL
Keck	NULL
for	NULL
critically	NULL
reading	NULL
the	NULL
manuscript	NULL
.	NULL

We	NULL
thank	NULL
G.	NULL
Branlant	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

We	NULL
acknowledge	NULL
C.	NULL
Lacoste	NULL
,	NULL
O.	NULL
Partouche	NULL
,	NULL
B.	NULL
Rutten	NULL
,	NULL
and	NULL
E.	NULL
Spieser	NULL
for	NULL
their	NULL
expert	NULL
technical	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Allenby	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
T.	NULL
Bocquel	NULL
,	NULL
M.	NULL
Sauders	NULL
,	NULL
M.	NULL
Kazmer	NULL
,	NULL
J.	NULL
Speck	NULL
,	NULL
M.	NULL
Rosenberger	NULL
,	NULL
A.	NULL
Lovey	NULL
,	NULL
P.	NULL
Kastner	NULL
,	NULL
J.	NULL
F.	NULL
Grippo	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
and	NULL
A	NULL
.	NULL

A.	NULL
Levin	NULL
.	NULL

1993	NULL
.	NULL

Retinoic	NULL
acid	NULL
receptors	NULL
and	NULL
retinoid	NULL
X	NULL
receptors	NULL
:	NULL
interactions	NULL
with	NULL
endogenous	NULL
retinoic	NULL
acids	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:30-34	NULL
.	NULL

2	NULL
.	NULL

Apfel	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
F.	NULL
Bauer	NULL
,	NULL
M.	NULL
Crettaz	NULL
,	NULL
L.	NULL
Forni	NULL
,	NULL
M.	NULL
Kamber	NULL
,	NULL
F.	NULL
Kaufmann	NULL
,	NULL
P.	NULL
LeMotte	NULL
,	NULL
W.	NULL
Pirson	NULL
,	NULL
and	NULL
M.	NULL
Klaus	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
retinoic	NULL
acid	NULL
receptor	NULL
«	NULL
antagonist	NULL
selectively	NULL
counteracts	NULL
retinoic	NULL
acid	NULL
effects	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:7129-7133	NULL
.	NULL

3	NULL
.	NULL

Apfel	NULL
,	NULL
C.	NULL
M.	NULL
Crettaz	NULL
,	NULL
G.	NULL
Siegentaler	NULL
,	NULL
and	NULL
W.	NULL
Hunziker	NULL
.	NULL

Synthetic	NULL
retinoids	NULL
:	NULL
differential	NULL
binding	NULL
to	NULL
retinoic	NULL
acid	NULL
receptors	NULL
,	NULL
p.	NULL
110-120	NULL
.	NULL

1990	NULL
.	NULL

In	NULL
P.	NULL
Saurat	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Retinoids	NULL
:	NULL
10	NULL
years	NULL
on	NULL
.	NULL

S.	NULL
Karger	NULL
,	NULL
Basel	NULL
.	NULL

4	NULL
.	NULL

Apfel	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
M.	NULL
Kamber	NULL
,	NULL
M.	NULL
Klaus	NULL
,	NULL
P.	NULL
Mobr	NULL
,	NULL
S.	NULL
Keidel	NULL
,	NULL
and	NULL
P.	NULL
LeMotte	NULL
.	NULL

1995	NULL
.	NULL

Enhancement	NULL
of	NULL
HL-60	NULL
differentiation	NULL
by	NULL
a	NULL
new	NULL
class	NULL
of	NULL
retinoids	NULL
with	NULL
selective	NULL
activity	NULL
on	NULL
retinoid	NULL
X	NULL
receptor	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:30765-30772	NULL
.	NULL

5	NULL
.	NULL

Barettino	NULL
,	NULL
D.	NULL
,	NULL
M.	NULL
Feigenbutz	NULL
,	NULL
R.	NULL
Valcarcel	NULL
,	NULL
and	NULL
H.	NULL
G.	NULL
Stunnenberg	NULL
.	NULL

1994	NULL
.	NULL

Improved	NULL
method	NULL
for	NULL
PCR-mediated	NULL
site-directed	NULL
mutagenesis	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

22:541-542	NULL
.	NULL

5392	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

LAMOUR	NULL
ET	NULL
AL	NULL
.	NULL

.	NULL

Benbrook	NULL
,	NULL
D.	NULL
,	NULL
E.	NULL
Lernhardt	NULL
,	NULL
and	NULL
M.	NULL
Pfah	NULL
]	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
new	NULL
retinoic	NULL
acid	NULL
recep-	NULL
tor	NULL
identified	NULL
from	NULL
a	NULL
hepatocellular	NULL
carcinoma	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
333:669-672.	NULL
.	NULL

Bérard	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
Gaboury	NULL
,	NULL
M.	NULL
Landers	NULL
,	NULL
Y	NULL
.	NULL

De	NULL
Repentigny	NULL
,	NULL
B.	NULL
Houle	NULL
,	NULL
R.	NULL
Kothary	NULL
,	NULL
and	NULL
W.	NULL
E.	NULL
C.	NULL
Bradley	NULL
.	NULL

1994	NULL
.	NULL

Hyperplasia	NULL
and	NULL
tumours	NULL
in	NULL
lung	NULL
,	NULL
breast	NULL
and	NULL
other	NULL
tissues	NULL
in	NULL
mice	NULL
carrying	NULL
a	NULL
RARB4-like	NULL
transgene	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:5570-5580.	NULL
.	NULL

Bourguet	NULL
,	NULL
W.	NULL
,	NULL
M.	NULL
Ruff	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
H.	NULL
Gronemeyer	NULL
,	NULL
and	NULL
D.	NULL
Moras	NULL
.	NULL

1995	NULL
.	NULL

Crystal	NULL
structure	NULL
of	NULL
the	NULL
ligand	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
human	NULL
nuclear	NULL
receptor	NULL
RXRa	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
375:377-382.	NULL
.	NULL

Brand	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
M.	NULL
Petkovich	NULL
,	NULL
A.	NULL
Krust	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
H.	NULL
de	NULL
The	NULL
,	NULL
A.	NULL
Marchio	NULL
,	NULL
P.	NULL
Fiollais	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
second	NULL
human	NULL
retinoic	NULL
acid	NULL
receptor	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
332:850-853	NULL
.	NULL

Chen	NULL
,	NULL
L.	NULL
X.	NULL
,	NULL
Z.	NULL
Zhang	NULL
,	NULL
A.	NULL
Scafonas	NULL
,	NULL
R.	NULL
C.	NULL
Cavallis	NULL
,	NULL
J.	NULL
L.	NULL
Gabriel	NULL
,	NULL
K.	NULL
J	NULL
.	NULL

Soprano	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Soprano	NULL
.	NULL

1995	NULL
.	NULL

Arginine	NULL
132	NULL
of	NULL
cellular	NULL
retinoic	NULL
acid-binding	NULL
protein	NULL
(	NULL
type	NULL
II	NULL
)	NULL
is	NULL
important	NULL
for	NULL
binding	NULL
of	NULL
retinoic	NULL
acid	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:4518-4525	NULL
.	NULL

Dallery	NULL
,	NULL
N.	NULL
,	NULL
B.	NULL
Sablonni¢re	NULL
,	NULL
I.	NULL
Grillier	NULL
,	NULL
P.	NULL
Formstecher	NULL
,	NULL
and	NULL
M.	NULL
Dautrevaux	NULL
.	NULL

1993	NULL
.	NULL

Purification	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
the	NULL
ligand-binding	NULL
domain	NULL
from	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
«	NULL
:	NULL
evidence	NULL
that	NULL
sulfhydryl	NULL
groups	NULL
are	NULL
involved	NULL
in	NULL
ligand-receptor	NULL
interactions	NULL
.	NULL

Biochemistry	NULL
32:12428-12436	NULL
.	NULL

De	NULL
The	NULL
H	NULL
,	NULL
M.	NULL
Vivanco-Ruiz	NULL
,	NULL
P.	NULL
Tiollais	NULL
,	NULL
H.	NULL
Stunnenberg	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
retinoic	NULL
acid	NULL
responsive	NULL
element	NULL
in	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
B	NULL
gene	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
343:177-180	NULL
.	NULL

Giguere	NULL
,	NULL
V.	NULL
,	NULL
E.	NULL
S.	NULL
Ong	NULL
,	NULL
P.	NULL
Segui	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1987	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
receptor	NULL
for	NULL
the	NULL
morphogen	NULL
retinoic	NULL
acid	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
330:624-629	NULL
.	NULL

Green	NULL
,	NULL
S.	NULL
,	NULL
I.	NULL
Issemann	NULL
,	NULL
and	NULL
I.	NULL
Sheer	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
versatile	NULL
in	NULL
vivo	NULL
eukaryotic	NULL
expression	NULL
vector	NULL
for	NULL
protein	NULL
engineering	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

16:369	NULL
.	NULL

Henion	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Weston	NULL
.	NULL

1993	NULL
.	NULL

Retinoic	NULL
acid	NULL
selectively	NULL
promotes	NULL
the	NULL
survival	NULL
and	NULL
proliferation	NULL
of	NULL
neurogenic	NULL
precursors	NULL
in	NULL
cultures	NULL
of	NULL
neural	NULL
crest	NULL
cell	NULL
populations	NULL
.	NULL

Dev	NULL
.	NULL

Biol	NULL
.	NULL

161:243-250	NULL
.	NULL

Heyman	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
D.	NULL
J.	NULL
Mangelsdorf	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Dyck	NULL
,	NULL
R.	NULL
B.	NULL
Stein	NULL
,	NULL
G.	NULL
Eichele	NULL
,	NULL
R.	NULL
Evans	NULL
,	NULL
and	NULL
C.	NULL
Thaller	NULL
.	NULL

1992	NULL
.	NULL

9-Cis	NULL
retinoic	NULL
acid	NULL
is	NULL
a	NULL
high	NULL
affinity	NULL
ligand	NULL
for	NULL
the	NULL
retinoid	NULL
X	NULL
receptor	NULL
.	NULL

Cell	NULL
68:397-406	NULL
.	NULL

Kastner	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
A.	NULL
Krust	NULL
,	NULL
C.	NULL
Mendelsohn	NULL
,	NULL
J.-M.	NULL
Garnier	NULL
,	NULL
A.	NULL
Zelent	NULL
,	NULL
P.	NULL
Leroy	NULL
,	NULL
A.	NULL
Staub	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1990	NULL
.	NULL

Murine	NULL
forms	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
y	NULL
with	NULL
specific	NULL
patterns	NULL
of	NULL
expression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
8:2700-2704	NULL
.	NULL

17a.Keidel	NULL
,	NULL
S.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

Keidel	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
LeMotte	NULL
,	NULL
and	NULL
C.	NULL
M.	NULL
Apfel	NULL
.	NULL

1994	NULL
.	NULL

Different	NULL
agonist-	NULL
and	NULL
antagonist-induced	NULL
conformational	NULL
changes	NULL
in	NULL
retinoic	NULL
acid	NULL
receptors	NULL
analyzed	NULL
by	NULL
protease	NULL
mapping	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:287-298	NULL
.	NULL

Krust	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Kastner	NULL
,	NULL
M.	NULL
Petkovich	NULL
,	NULL
A.	NULL
Zelent	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
third	NULL
human	NULL
retinoic	NULL
acid	NULL
receptor	NULL
,	NULL
hRARy	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:5310-5314	NULL
.	NULL

Lefebvre	NULL
,	NULL
B.	NULL
,	NULL
C.	NULL
Rachez	NULL
,	NULL
P.	NULL
Formstecher	NULL
,	NULL
and	NULL
P.	NULL
Lefebvre	NULL
.	NULL

1995	NULL
.	NULL

Structural	NULL
determinants	NULL
of	NULL
the	NULL
ligand-binding	NULL
site	NULL
of	NULL
the	NULL
human	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a.	NULL
Biochemistry	NULL
34:5477-5485	NULL
.	NULL

Lehmann	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
M.	NULL
I.	NULL
Dawson	NULL
,	NULL
P.	NULL
D.	NULL
Hobbs	NULL
,	NULL
M.	NULL
Husmann	NULL
,	NULL
and	NULL
M.	NULL
Pfahl	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
of	NULL
retinoids	NULL
with	NULL
nuclear	NULL
receptor	NULL
subtype-selective	NULL
ac-tivities	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

51:4804-4809	NULL
.	NULL

Leid	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
Kastner	NULL
,	NULL
R.	NULL
Lyons	NULL
,	NULL
H.	NULL
Nakshrati	NULL
,	NULL
M.	NULL
Saunders	NULL
,	NULL
T.	NULL
Zacharewski	NULL
,	NULL
J.-Y	NULL
.	NULL

Chen	NULL
,	NULL
A.	NULL
Staub	NULL
,	NULL
J.M	NULL
.	NULL

Garnier	NULL
,	NULL
S.	NULL
Mader	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1992	NULL
.	NULL

Purification	NULL
,	NULL
cloning	NULL
,	NULL
and	NULL
RXR	NULL
identity	NULL
of	NULL
the	NULL
HeLa	NULL
cell	NULL
factor	NULL
with	NULL
which	NULL
RAR	NULL
and	NULL
TR	NULL
heterodimerizes	NULL
to	NULL
bind	NULL
target	NULL
sequences	NULL
efficiently	NULL
.	NULL

Cell	NULL
68:377-395	NULL
.	NULL

LeMotte	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
S.	NULL
Keidel	NULL
,	NULL
and	NULL
C.	NULL
M.	NULL
Apfel	NULL
.	NULL

1996	NULL
.	NULL

Phytanic	NULL
acid	NULL
is	NULL
a	NULL
retinoid	NULL
X	NULL
receptor	NULL
ligand	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

236:328-333	NULL
.	NULL

Leroy	NULL
,	NULL
P.	NULL
,	NULL
A.	NULL
Krust	NULL
,	NULL
A.	NULL
Zelent	NULL
,	NULL
C.	NULL
Mendelsohn	NULL
,	NULL
J.-M.	NULL
Garnier	NULL
,	NULL
P.	NULL
Kastner	NULL
,	NULL
A.	NULL
Dierich	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1991	NULL
.	NULL

Multiple	NULL
isoforms	NULL
of	NULL
the	NULL
mouse	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
are	NULL
generated	NULL
by	NULL
alternative	NULL
splicing	NULL
and	NULL
differential	NULL
induction	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:59-69.	NULL
.	NULL

Levin	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
L.	NULL
J.	NULL
Sturzenbecker	NULL
,	NULL
S.	NULL
Kazmer	NULL
,	NULL
T.	NULL
Bosakowski	NULL
,	NULL
C.	NULL
Huselton	NULL
,	NULL
G.	NULL
Allenby	NULL
,	NULL
J.	NULL
Speck	NULL
,	NULL
C.	NULL
Kratzeisen	NULL
,	NULL
M.	NULL
Rosenberger	NULL
,	NULL
A.	NULL
Lovey	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Grippo	NULL
.	NULL

1992	NULL
.	NULL

9-Cis	NULL
retinoic	NULL
acid	NULL
stereoisomer	NULL
binds	NULL
and	NULL
activates	NULL
the	NULL
nuclear	NULL
receptor	NULL
RXRa	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
355:359-361	NULL
.	NULL

Lohnes	NULL
,	NULL
D.	NULL
,	NULL
P.	NULL
Kastner	NULL
,	NULL
A.	NULL
Dierich	NULL
,	NULL
M.	NULL
Mark	NULL
,	NULL
M.	NULL
LeMeur	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1993	NULL
.	NULL

Function	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
y	NULL
in	NULL
the	NULL
mouse	NULL
.	NULL

Cell	NULL
73:643-658	NULL
.	NULL

Lohnes	NULL
,	NULL
D.	NULL
,	NULL
M.	NULL
Mark	NULL
,	NULL
C.	NULL
Mendelsohn	NULL
,	NULL
P.	NULL
Dollé	NULL
,	NULL
A.	NULL
Dierich	NULL
,	NULL
P.	NULL
Gorry	NULL
,	NULL
A	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

Gansmuller	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1994	NULL
.	NULL

Function	NULL
of	NULL
the	NULL
retinoic	NULL
acid	NULL
receptors	NULL
(	NULL
RARs	NULL
)	NULL
during	NULL
development	NULL
.	NULL

I.	NULL
Craniofacial	NULL
and	NULL
skeletal	NULL
abnormalities	NULL
in	NULL
RAR	NULL
double	NULL
mutants	NULL
.	NULL

Development	NULL
120:2723-2748	NULL
.	NULL

Lu	NULL
,	NULL
X.	NULL
J.	NULL
,	NULL
S.	NULL
Deb	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Soares	NULL
.	NULL

1991	NULL
.	NULL

Spontancous	NULL
differentiation	NULL
of	NULL
trophoblast	NULL
cells	NULL
along	NULL
the	NULL
spongiotrophoblast	NULL
cell	NULL
pathway	NULL
:	NULL
expression	NULL
of	NULL
members	NULL
of	NULL
the	NULL
placental	NULL
prolactin	NULL
gene	NULL
and	NULL
modulation	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Dev	NULL
.	NULL

Biol	NULL
.	NULL

163:86-97	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
U.	NULL
Borgmeyer	NULL
,	NULL
R.	NULL
A.	NULL
Heyman	NULL
,	NULL
J.	NULL
Y.	NULL
Zhou	NULL
,	NULL
E.	NULL
S.	NULL
Ong	NULL
,	NULL
A.	NULL
E.	NULL
Oro	NULL
,	NULL
A.	NULL
Kakizuka	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
three	NULL
RXR	NULL
genes	NULL
that	NULL
mediate	NULL
the	NULL
activation	NULL
of	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

6:329-344	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
E.	NULL
S.	NULL
Ong	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Dyck	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1990	NULL
.	NULL

Nuclear	NULL
receptor	NULL
that	NULL
identifies	NULL
a	NULL
novel	NULL
retinoic	NULL
acid	NULL
response	NULL
pathway	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
345:224-229	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
S.	NULL
A.	NULL
Kliewer	NULL
,	NULL
U.	NULL
Borgmeyer	NULL
,	NULL
E.	NULL
S.	NULL
Ong	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
direct	NULL
repeat	NULL
in	NULL
the	NULL
cellular	NULL
retinol-binding	NULL
protein	NULL
type	NULL
II	NULL
gene	NULL
confers	NULL
differential	NULL
regulation	NULL
by	NULL
RXR	NULL
and	NULL
RAR	NULL
.	NULL

Cell	NULL
66:555-561	NULL
.	NULL

Mendelsohn	NULL
,	NULL
C.	NULL
,	NULL
D.	NULL
Lohnes	NULL
,	NULL
D.	NULL
Décimo	NULL
,	NULL
T.	NULL
Lufkin	NULL
,	NULL
M.	NULL
LeMeur	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
and	NULL
M.	NULL
Mark	NULL
.	NULL

1994	NULL
.	NULL

Function	NULL
of	NULL
the	NULL
retinoic	NULL
acid	NULL
receptors	NULL
(	NULL
RARs	NULL
)	NULL
during	NULL
development	NULL
.	NULL

II	NULL
.	NULL

Multiple	NULL
abnormalities	NULL
at	NULL
various	NULL
stages	NULL
of	NULL
organogenesis	NULL
in	NULL
RAR	NULL
double	NULL
mutants	NULL
.	NULL

Development	NULL
120:2749-2771	NULL
.	NULL

Ostrowski	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
Hammer	NULL
,	NULL
T.	NULL
Roalsvig	NULL
,	NULL
K.	NULL
Pokornowski	NULL
,	NULL
and	NULL
P.	NULL
R.	NULL
Reczek	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
N-terminal	NULL
portion	NULL
of	NULL
domain	NULL
E	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
and	NULL
B	NULL
is	NULL
essential	NULL
for	NULL
recognition	NULL
of	NULL
retinoic	NULL
acid	NULL
and	NULL
various	NULL
analogs	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:1812-1816	NULL
.	NULL

Parker	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
G.	NULL
V.	NULL
Sherbet	NULL
.	NULL

1992	NULL
.	NULL

Modulation	NULL
of	NULL
gene	NULL
function	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Pathobiology	NULL
60:278-283	NULL
.	NULL

Petkovich	NULL
,	NULL
M.	NULL
,	NULL
N.	NULL
J	NULL
.	NULL

Brand	NULL
,	NULL
A.	NULL
Krust	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
human	NULL
retinoic	NULL
acid	NULL
receptor	NULL
which	NULL
belongs	NULL
to	NULL
the	NULL
family	NULL
of	NULL
nuclear	NULL
receptors	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
330:444-450	NULL
.	NULL

Ponzoni	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Lanciotti	NULL
,	NULL
P.	NULL
G.	NULL
Montaldo	NULL
,	NULL
and	NULL
P.	NULL
Cornagliaferraris	NULL
.	NULL

1991	NULL
.	NULL

Gamma-interferon	NULL
,	NULL
retinoic	NULL
acid	NULL
and	NULL
cytosine	NULL
arabinoside	NULL
induce	NULL
neuroblas-toma	NULL
differentiation	NULL
by	NULL
different	NULL
mechanisms	NULL
.	NULL

Cell	NULL
.	NULL

Mol	NULL
.	NULL

Neurobiol	NULL
.	NULL

11:397-413	NULL
.	NULL

Ragsdale	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
M.	NULL
Petkovich	NULL
,	NULL
P.	NULL
B	NULL
.	NULL

Gates	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
and	NULL
J.	NULL
Brockes	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
novel	NULL
retinoic	NULL
acid	NULL
receptor	NULL
in	NULL
regenerative	NULL
tissues	NULL
of	NULL
the	NULL
newt	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
341:654-657.	NULL
.	NULL

Redfern	NULL
,	NULL
C.	NULL
P.	NULL
F.	NULL
1992	NULL
.	NULL

Retinoic	NULL
acid	NULL
receptor	NULL
.	NULL

Pathobiology	NULL
60:254-263.	NULL
.	NULL

Renaud	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
N.	NULL
Rochel	NULL
,	NULL
M.	NULL
Ruff	NULL
,	NULL
V.	NULL
Vivat	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
H.	NULL
Gronemeyer	NULL
,	NULL
and	NULL
D.	NULL
Moras	NULL
.	NULL

1995	NULL
.	NULL

Crystal	NULL
structure	NULL
of	NULL
the	NULL
RAR-y	NULL
ligand-binding	NULL
domain	NULL
bound	NULL
to	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
378:681-689.	NULL
.	NULL

Rodriguez-Tebar	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
H.	NULL
Rohrer	NULL
.	NULL

1991	NULL
.	NULL

Retinoic	NULL
acid	NULL
induces	NULL
NGF	NULL
dependent	NULL
survival	NULL
response	NULL
and	NULL
high-affinity	NULL
NGF	NULL
receptors	NULL
in	NULL
immature	NULL
chick	NULL
sympathetic	NULL
neurons	NULL
.	NULL

Development	NULL
112:813-820.	NULL
.	NULL

Ruiz	NULL
i	NULL
Altaba	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
T.	NULL
M.	NULL
Jessel	NULL
.	NULL

1991	NULL
.	NULL

Retinoic	NULL
acid	NULL
modifies	NULL
the	NULL
pattern	NULL
of	NULL
cell	NULL
differentiation	NULL
in	NULL
the	NULL
central	NULL
nervous	NULL
system	NULL
of	NULL
neurula	NULL
stage	NULL
Xenopus	NULL
embryos	NULL
.	NULL

Development	NULL
112:945-958	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Scatchard	NULL
,	NULL
G.	NULL
1949	NULL
.	NULL

The	NULL
attractions	NULL
of	NULL
proteins	NULL
for	NULL
small	NULL
molecules	NULL
and	NULL
ions	NULL
.	NULL

Ann	NULL
.	NULL

N.Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

51:660-672	NULL
.	NULL

Studier	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
and	NULL
B	NULL
.	NULL

A.	NULL
Moffat	NULL
.	NULL

1986	NULL
.	NULL

Use	NULL
of	NULL
bacteriophage	NULL
T7	NULL
RNA	NULL
polymerase	NULL
to	NULL
direct	NULL
selective	NULL
high-level	NULL
expression	NULL
of	NULL
cloned	NULL
genes	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

189:113-130	NULL
.	NULL

Tairis	NULL
,	NULL
N.	NULL
,	NULL
J.	NULL
L.	NULL
Gabriel	NULL
,	NULL
L	NULL
I	NULL
I	NULL
M.	NULL
Gyda	NULL
,	NULL
K.	NULL
J	NULL
.	NULL

Soprano	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Soprano	NULL
.	NULL

1994	NULL
.	NULL

Arg	NULL
``	NULL
``	NULL
``	NULL
and	NULL
Lys*	NULL
``	NULL
``	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor-B	NULL
are	NULL
important	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
retinoic	NULL
acid	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:19516-19522	NULL
.	NULL

Tairis	NULL
,	NULL
N.	NULL
,	NULL
J.	NULL
L.	NULL
Gabriel	NULL
,	NULL
K.	NULL
J	NULL
.	NULL

Soprano	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Soprano	NULL
.	NULL

1995	NULL
.	NULL

Alteration	NULL
in	NULL
the	NULL
retinoid	NULL
specificity	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor-8	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
Arg	NULL
``	NULL
*	NULL
and	NULL
Lys®	NULL
``	NULL
``	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:18380-18387	NULL
.	NULL

Tate	NULL
,	NULL
B.	NULL
F.	NULL
,	NULL
and	NULL
J.	NULL
G.	NULL
Grippo	NULL
.	NULL

1995	NULL
.	NULL

Mutagenesis	NULL
of	NULL
the	NULL
ligand	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
human	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
identifies	NULL
critical	NULL
residues	NULL
for	NULL
9-cis-retinoic	NULL
acid	NULL
binding	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:20258-20263	NULL
.	NULL

Zelent	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Krust	NULL
,	NULL
M.	NULL
Petkovich	NULL
,	NULL
P.	NULL
Kastner	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1989	NULL
.	NULL

Cloning	NULL
of	NULL
murine	NULL
«	NULL
and	NULL
B	NULL
retinoic	NULL
acid	NULL
receptors	NULL
and	NULL
a	NULL
novel	NULL
receptor	NULL
y	NULL
predominantly	NULL
expressed	NULL
in	NULL
skin	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
339:714-717	NULL
.	NULL

